Derivation of embryonic stem cells and embryo-derived cells

ABSTRACT

This present invention provides novel methods for deriving embryonic stem cells and embryo-derived cells from an embryo without requiring destruction of the embryo. The invention further provides cells and cell lines derived without embryo destruction, and the use of the cells for therapeutic and research purposes. It also relates to novel methods of establishing and storing an autologous stem cell line prior to implantation of an embryo, e.g., in conjunction with reproductive therapies such as IVF.

CROSS REFERENCE TO RELATED APPLICATIONS

This application in a continuation-in-part of and claims the benefit ofpriority to U.S. application Ser. No. 11/267,555, filed Nov. 4, 2005,which claims priority to U.S. Provisional Application Nos.: 60/624,827,filed Nov. 4, 2004; 60/662,489, filed Mar. 15, 2005; 60/687,158, filedJun. 3, 2005; 60/723,066, filed Oct. 3, 2005; and 60/726,775, filed onOct. 14, 2005. This application also claims the benefit of U.S.Provisional Application Nos. 60/797,449, filed May 3, 2006; 60/798,065,filed May 4, 2006; 60/831,698, filed Jul. 17, 2006, and 60/839,622,filed Aug. 23, 2006. The disclosures of each of the foregoingapplications are hereby incorporated by reference in their entirety.

FIELD OF THE INVENTION

This invention generally relates to novel methods for deriving embryonicstem (ES) cells and embryo-derived (ED) cells, those cells and celllines, and the use of the cells for therapeutic and research purposes.It also relates to novel methods of establishing and storing anautologous stem cell line prior to implantation of an embryo, e.g. inconjunction with assisted reproductive technologies such as in vitrofertilization.

BACKGROUND OF THE INVENTION

With few exceptions, embryonic stem cells have only been grown fromblastocyst-stage embryos. ES cell lines are conventionally isolated fromthe inner cell mass of blastocysts. There are several drawbacks to thetechniques used to create these cells. From the perspective of thetechnique, the culturing of embryos to blastocysts occasionally has arelatively low success rate. Additionally, certain members of the publicobject to embryonic stem (ES) cell research using cell lines derivedfrom the inner cell mass of blastocysts because this derivationprocedure destroys the preimplantation, blastocyst-stage embryo. Assuch, the blastocyst-stage embryo from which ES cells are conventionallyproduced cannot be cryopreserved, frozen for later use, or permitted todevelop further.

The present invention provides novel methods for deriving ES cells, EScell lines, and other embryo-derived (ED) cells for use in research andmedicine. The methods described herein permit the derivation of EScells, ES cell lines, and other ED cells from embryos but without theneed to destroy those embryos.

SUMMARY OF THE INVENTION

The present invention provides novel methods for deriving embryonic stemcells and embryo-derived cells from an embryo, those cells and celllines, and uses of the embryonic stem cells and cell lines fortherapeutic and research purposes. It also relates to a method ofestablishing and storing an autologous stem cell line from a blastomereretrieved prior to implantation of an embryo, e.g. in conjunction withassisted reproductive technologies such as in vitro fertilization(“IVF”).

In a first aspect, the invention provides a method of producing humanembryonic stem (ES) cells. The method generally comprises culturing ablastomere obtained from a human embryo. In certain embodiments, theblastomere is cultured in medium containing less than 5 mM glucoseand/or having an osmolarity of less than 310 mosm to generate a clusterof two or more blastomeres. The cultured cluster of two or moreblastomeres is contacted (directly or indirectly) with embryonic orfetal cells, and the cluster of two or more blastomeres is then furthercultured (in the presence or absence of embryonic or fetal cells) toproduce ES cells.

In certain embodiments, the method initially comprises culturing ablastomere obtained from a human embryo for at least one day in mediumcontaining less than 5 mM glucose and/or having an osmolarity of lessthan 310 mosm.

In certain embodiments, the method is similarly used to producepartially differentiated cells directly from a blastomere without theneed to first derive ES cells.

In certain embodiments, the cultured cluster of two or more blastomerescomprises an aggregate of two or more blastomeres, and the aggregate oftwo or more blastomeres is contacted with embryonic or fetal cells.

In certain embodiments, during or following contact with embryonic orfetal cells, the cluster of two or more blastomeres is cultured inmedium containing at least 5 mM glucose and/or having an osmolarity ofat least 310 mosm.

In certain embodiments, two or more blastomeres are initially obtainedfrom an embryo, and the two or more blastomeres are initially culturedin medium containing less than 5 mM glucose and/or having an osmolarityof less than 310 mosm. These blastomeres may be from the same or adifferent embryo, and these blastomeres may be cultured in directcontact with one another or without contact but in the same culturevessel or microdrop.

In certain embodiments of any of the foregoing or following, obtainingthe blastomere from a human embryo yields a blastomere and a remaininghuman embryo, and the remaining human embryo is not destroyed followingobtaining the blastomere. In certain embodiments, the remaining embryois viable. In certain embodiments, the remaining embryo is cultured forone or more days following removal of the blastomere to assessviability. In certain embodiments, the remaining embryo iscryopreserved.

In certain embodiments of any of the foregoing, a blastomere is obtainedfrom a human embryo after compaction of the morula. In certainembodiments, the blastomere is obtained from a human embryo beforeformation of the blastocoel. In certain embodiments, the blastomere isobtained from a 4-16 cell embryo, a 4-10 cell human embryo, or a 4-8cell human embryo.

The cluster of two or more blastomeres and the embryonic or fetal cellsare directly or indirectly contacted with each other. In certainembodiments, the cluster of two or more blastomeres and the embryonic orfetal cells are not cultured as aggregates. In certain otherembodiments, the cluster of two or more blastomeres is indirectlycontacted with the embryonic or fetal cells.

In certain other embodiments, the cells (blastomeres, clusters ofblastomeres, and/or embryonic or fetal cells) are cultured in microdropculture.

In certain embodiments, the embryo (for example, a human embryo) waspreviously frozen and is thawed prior to obtaining the blastomere.

Various methods and combinations can be used to remove a blastomere froman embryo. Preferably, a blastomere is removed without substantiallydecreasing the viability of the remainder of the embryo. In other words,following removal of a blastomere, the remainder of the embryo cancontinue to grow. In certain embodiments, the ability to continue togrow and survive in culture for at least one day following blastomereremoval indicates that blastomere removal did not substantially decreaseviability. In certain embodiments, the blastomere is obtained bypartially or completely removing the zona pellucida surrounding thehuman embryo. In certain other embodiments, the blastomere is obtainedby immobilizing the embryo and tapping the immobilized embryo until theblastomere is isolated.

In certain embodiments in which embryonic or fetal cells are used,exemplary embryonic or fetal cells are human cells. In certainembodiments, the human embryonic or fetal cells are selected from humanES cells, human ED cells, human TS cells, human EG cells, placental stemcells, amniotic fluid cell or stem cells, or human embryo carcinomacells. In certain embodiments, the embryonic or fetal cells areoptionally cultured on a fibroblast feeder layer.

In certain embodiments, the blastomere or cluster of two or moreblastomeres is cultured with a factor that inhibits differentiation ofthe ES cells. In certain embodiments, recombinant Oct-4 is introducedinto the blastomere or endogenous Oct-4 is activated in the blastomereduring a step of culturing the blastomere to produce the human ES cells.

In certain embodiments, the ES cells or cell lines, for example thehuman ES cells or cell lines, are pluripotent. In certain embodiments,ES cells express one or more ES cell marker proteins selected from anyof Oct-4, alkaline phosphatase, SSEA-3, SSEA-4, TRA-1-60 and TRA-1-81.

In certain embodiments, the blastomere undergoes cell division and oneprogeny cell is used for genetic testing and a different progeny cell isused to produce human ES cells.

In certain embodiments of any of the foregoing, the method furthercomprises isolating the ES cells derived from the blastomere andculturing the ES cells to generate an ES cell line.

In another aspect, the invention provides a method of generatingautologous stem cells concomitantly to performing genetic diagnosis. Ablastomere is removed from an embryo, as is typically done duringpre-implantation genetic diagnosis (PGD). The blastomere is cultured andpermitted to divide at least once. After division, one progeny cell isused for genetic diagnosis, and the other progeny cell is furthercultured (using any of the methods described herein) to produce an EScell or ES cell line. Such ES cell or ES cell lines would be a suitablesource of autologous cells and tissue for the embryo or individual thatresulted from that embryo.

In another aspect, the invention provides human ES cells derived from ahuman embryo but without destroying the human embryo. In certainaspects, the ES cells are produced using any of the methods describedherein.

In another aspect, the invention provides a human ES cell line derivedfrom a human embryo but without destroying the human embryo. In certainaspects, the ES cell lines is produced using any of the methodsdescribed herein.

In certain embodiments, the human ES cell or ES cell line has one ormore characteristics of previously identified, blastocyst-derived EScell lines. In certain embodiments, the human ES cell or ES cell line ispluripotent and expresses one or more ES cell marker proteins selectedfrom any of Oct-4, SSEA-1, nanog, alkaline phosphatase and Res-1. Incertain embodiments, the human ES cell or ES cell line maintains anormal karyotype.

In another aspect, the invention provides a differentiated cell ortissue directly produced from a blastomere.

In another aspect, the invention provides a differentiated cell ortissue derived from a human ES cell or cell line produced from ablastomere. In certain embodiments, the differentiated cell or tissue islineage committed. In certain embodiments, the differentiated cell ortissue is a mesodermal, endodermal or ectodermal cell or tissue. Incertain embodiments, the differentiated cell or tissue is partially orterminally differentiated.

In another aspect, the invention provides a method of producing adesired differentiated cell or tissue by inducing differentiation of ahuman ES cell or cell line into the desired cell or tissue. In certainembodiments, the method comprises contacting an ES cell or ES cell lineproduced from a blastomere with one or more agents that promotedifferentiation of an ES cell or cell line along a particulardevelopmental lineage.

In another aspect, the invention provides compositions and preparationscomprising a differentiated cell or tissue produced from an ES cell orcell line derived from a blastomere. In certain embodiments, thecompositions and preparations are pharmaceutical preparations formulatedin a pharmaceutically acceptable carrier.

In another aspect, the invention provides a method of treating adisorder amenable to cell therapy in a patient by administering aneffective amount of an ES cell or cell line produced from a blastomereusing any of the methods described herein.

In another aspect, the invention provides a method of treating adisorder amenable to cell therapy in a patient by administering to thepatient an effective amount of a differentiated cell or tissue producedeither directly from a blastomere culture or produced from an ES cell orcell line.

In another aspect, the invention provides a method of producing atrophoblast stem (TS) cell. The method comprises culturing a blastomereobtained from a human embryo in medium containing less than 5 mM glucoseand/or having an osmolarity of less than 310 mosm to generate a clusterof two or more blastomeres; directly or indirectly contacting thecultured cluster of two or more blastomeres to embryonic or fetal cells;and further culturing the cluster of two or more blastomeres until TScells are produced.

In certain embodiments, method comprises culturing a blastomere obtainedfrom a human embryo for at least one day in medium containing less than5 mM glucose and/or having an osmolarity of less than 310 mosm.

In certain embodiments, the cultured cluster of two or more blastomerescomprises an aggregate of two or more blastomeres, and the aggregate oftwo or more blastomeres is contacted with embryonic or fetal cells.

In certain embodiments, during or following contact with embryonic orfetal cells, the cluster of two or more blastomeres is cultured inmedium containing at least 5 mM glucose and/or having an osmolarity ofat least 310 mosm.

In certain embodiments, the one that one blastomere is initiallyobtained from an embryo, and the two or more blastomeres are initiallycultured in medium containing less than 5 mM glucose and/or having anosmolarity of less than 310 mosm. These blastomeres may be from the sameor a different embryo, and these blastomeres may be cultured in directcontact with one another or without contact but in the same culturevessel or microdrop.

In certain embodiments of any of the foregoing or following, obtainingthe blastomere from a human embryo yields a blastomere and a remaininghuman embryo, and the remaining human embryo is not destroyed followingobtaining the blastomere. In certain embodiments, the remaining embryois viable. In certain embodiments, the remaining embryo is cultured forone or more days following removal of the blastomere to assessviability. In certain embodiments, the remaining embryo iscryopreserved.

In certain embodiments of any of the foregoing, a blastomere is obtainedfrom a human embryo after compaction of the morula. In certainembodiments, the blastomere is obtained from a human embryo beforeformation of the blastocoel. In certain embodiments, the blastomere isobtained from a 4-16 cell embryo, a 4-10 cell human embryo, or a 4-8cell human embryo.

The cluster of two or more blastomeres and the embryonic or fetal cellsare directly or indirectly contacted with each other. In certainembodiments, the cluster of two or more blastomeres and the embryonic orfetal cells are not cultured as aggregates. In certain otherembodiments, the cluster of two or more blastomeres is indirectlycontacted with the embryonic or fetal cells.

In certain other embodiments, the cells (blastomeres, clusters ofblastomeres, and/or embryonic or fetal cells) are cultured in microdropculture.

In certain embodiments, the embryo (for example, human embryo) waspreviously frozen and is thawed prior to obtaining the blastomere.

Various methods and combinations can be used to remove a blastomere froman embryo. Preferably, a blastomere is removed without substantiallydecreasing the viability of the remainder of the embryo. In other words,following removal of a blastomere, the remainder of the embryo cancontinue to grow. In certain embodiments, the ability to continue togrow and survive in culture for at least one day following blastomereremoval indicates that blastomere removal did not substantially decreaseviability. In certain embodiments, the blastomere is obtained bypartially or completely removing the zona pellucida surrounding thehuman embryo. In certain other embodiments, the blastomere is obtainedby immobilizing the embryo and tapping the immobilized embryo until theblastomere is isolated.

In certain embodiments in which embryonic or fetal cells are used,exemplary embryonic or fetal cells are human cells. In certainembodiments, the human embryonic or fetal cells are selected from humanES cells, human ED cells, human TS cells, human EG cells, placental stemcells, amniotic fluid cell or stem cells, or human embryo carcinomacells. In certain embodiments, the embryonic or fetal cells areoptionally cultured on a fibroblast feeder layer.

In certain embodiments, the method further comprises isolating the TScells derived from the blastomere. In certain embodiments, the methodfurther comprises establishing a TS cell line from the TS cells derivedfrom the blastomere.

In certain embodiments, exemplary TS cells or TS cell lines express atleast one TS cell marker protein selected from the any of cdx-2, fgfr2,PL-1 and human chorionic gonadotropin (hCG). In certain embodiments,exemplary TS cells or TS cell lines do not express Oct-4 or α-fetoprotein.

In another aspect, the invention provides a human TS cell derived from ahuman embryo but without destroying the human embryo. In certainembodiments, exemplary TS cells or TS cell lines express at least one TScell marker protein selected from the any of cdx-2, fgfr2, PL-1 andhuman chorionic gonadotropin (hCG). In certain embodiments, exemplary TScells or TS cell lines do not express Oct-4 or α-feto protein.

In another aspect, the invention provides a differentiated cell ortissue derived from a TS cell or TS cell line produced from ablastomere.

In another aspect, the invention provides a method of isolating ablastomere from an embryo. The method comprises immobilizing the embryoand tapping the immobilized embryo until a blastomere is isolated. Incertain embodiments, a single blastomere is isolated from the remainderof the embryo. In certain embodiments, multiple blastomeres are isolatedfrom the remainder of the embryo. In certain embodiments, this method iscombined with other methods used to obtain a blastomere from an embryo(e.g., removal of the zona pelucida, exposure to enzymes, exposure toCa2+ and/or Mg2+ free medium). In certain embodiments, the embryo isimmobilized using a micropipette. In certain embodiments, the embryo isa 4-16 cell stage embryo, a 4-10 cell stage embryo, or an 8-10 cellstage embryo.

In another aspect, the invention provides a method of conductingembryonic stem cell research without destroying a human embryo. Themethod comprises obtaining a human ES cell or ES cell line that isderived from a human embryo but without destroying the human embryo.Such lines may be generated using any of the methods for deriving EScell or cell lines from a blastomere. Once generated, the method furthercomprises conducting embryonic stem cell research using the human EScell or ES cell line.

In certain embodiments, conducting embryonic stem cell researchcomprises contacting the human ES cell or ES cell line with one or morefactors, and identifying factors that promote differentiation of the EScell or ES cell line to one or more mesodermal, endodermal, orectodermal cell types.

In another aspect, the invention provides a method of producing anembryonic stem (ES) cell. The method comprises culturing a blastomereobtained from a mammalian embryo to generate a cluster of two or moreblastomeres; directly or indirectly contacting the cultured cluster oftwo or more blastomeres with embryonic or fetal cells; and culturing thecluster of two or more blastomeres of (b) until ES cells are produced.

In certain embodiments, the cultured cluster of two or more blastomerescomprises an aggregate of two or more blastomeres, and the aggregate oftwo or more blastomeres is contacted with embryonic or fetal cells.

In certain embodiments, during or following contact with embryonic orfetal cells, the cluster of two or more blastomeres is cultured inmedium containing at least 5 mM glucose and/or having an osmolarity ofat least 310 mosm.

In certain embodiments, the one that one blastomere is initiallyobtained from an embryo, and the two or more blastomeres are initiallycultured in medium containing less than 5 mM glucose and/or having anosmolarity of less than 310 mosm. These blastomeres may be from the sameor a different embryo, and these blastomeres may be cultured in directcontact with one another or without contact but in the same culturevessel or microdrop.

In certain embodiments of any of the foregoing or following, obtainingthe blastomere from a embryo yields a blastomere and a remaining embryo,and the remaining embryo is not destroyed following obtaining theblastomere. In certain embodiments, the remaining embryo is viable. Incertain embodiments, the remaining embryo is cultured for one or moredays following removal of the blastomere to assess viability. In certainembodiments, the remaining embryo is cryopreserved.

In certain embodiments of any of the foregoing, a blastomere is obtainedfrom a embryo after compaction of the morula. In certain embodiments,the blastomere is obtained from an embryo before formation of theblastocoel. In certain embodiments, the blastomere is obtained from a4-16 cell embryo, a 4-10 cell embryo, or a 4-8 cell human embryo.

The cluster of two or more blastomeres and the embryonic or fetal cellsare directly or indirectly contacted with each other. In certainembodiments, the cluster of two or more blastomeres and the embryonic orfetal cells are not cultured as aggregates. In certain otherembodiments, the cluster of two or more blastomeres is indirectlycontacted with the embryonic or fetal cells.

In certain other embodiments, the cells (blastomeres, clusters ofblastomeres, and/or embryonic or fetal cells) are cultured in microdropculture.

In certain embodiments, the embryo (for example, a human embryo) waspreviously frozen and is thawed prior to obtaining the blastomere.

Various methods and combinations can be used to remove a blastomere froman embryo. Preferably, a blastomere is removed without substantiallydecreasing the viability of the remainder of the embryo. In other words,following removal of a blastomere, the remainder of the embryo cancontinue to growth. In certain embodiments, the ability to continue togrow and survive in culture for at least one day following blastomereremoval indicates that blastomere removal did not substantially decreaseviability. In certain embodiments, the blastomere is obtained bypartially or completely removing the zona pellucida surrounding thehuman embryo. In certain other embodiments, the blastomere is obtainedby immobilizing the embryo and tapping the immobilized embryo until theblastomere is isolated.

In certain embodiments in which embryonic or fetal cells are used,exemplary embryonic or fetal are mouse cells or human cells. In certainembodiments, the embryonic or fetal cells are from the same species asthe blastomere. In certain embodiments, the human embryonic or fetalcells are selected from human ES cells, human ED cells, human TS cells,human EG cells, placental stem cells, amniotic fluid cells or stemcells, or human embryo carcinoma cells. In certain embodiments, theembryonic or fetal cells are optionally cultured on a fibroblast feederlayer.

In certain embodiments, the method further comprises the step ofisolating the ES cells derived from the blastomere and generating an EScell line.

In another aspect, the invention provides a method of producing EScells. The method comprises obtaining a blastomere from a mammalianembryo; culturing the blastomere to generate a cluster of two or moreblastomeres; aggregating the cluster of two or more blastomeres withembryonic or fetal cells; culturing the aggregated cluster of two ormore blastomeres and the embryonic or fetal cells until the aggregatedcluster of blastomeres exhibits properties of ES cells; and isolatingthe ES cells derived from the blastomere from the embryonic cells.

In another aspect, the invention provides a method of producing TScells. The method comprises: obtaining a blastomere from a mammalianembryo; culturing the blastomere to generate a cluster of two or moreblastomeres; aggregating the cluster of two or more blastomeres withembryonic or fetal cells; obtaining outgrowths from the cluster of twoor more blastomeres, wherein the outgrowths exhibit properties oftrophoblast or extraembryonic endoderm cells; contacting the outgrowthswith FGF-4 to produce TS cells; and isolating the TS cells derived fromthe blastomere.

In certain embodiments, the mammalian embryo is a human embryo and theTS cells are human cells. In certain other embodiments, the methodfurther comprises producing a TS cell line by culturing the TS cellsderived from the blastomere to produce a TS cell line.

In another aspect, the invention provides a method of producing humanembryonic stem (ES) cells. The method comprises: culturing a blastomereobtained from a human embryo in medium containing less than 5 mM glucoseand/or having an osmolarity of less than 310 mosm to generate a clusterof two or more blastomeres; directly or indirectly contacting thecultured cluster of two or more blastomeres with medium sufficient topromote the growth and survival of the cultured cluster of two or moreblastomeres; and further culturing the cluster of two or moreblastomeres to produce ES cells.

In certain embodiment, the method comprises culturing a blastomereobtained from a human embryo for at least one day in medium containingless than 5 mM glucose and/or having an osmolarity of less than 310 mosmto generate a cluster of two or more blastomeres.

In certain embodiments, the medium sufficient to promote the growth andsurvival of the cultured cluster of two or more blastomeres is mediumconditioned with embryonic or fetal cells. In certain other embodiments,the medium sufficient to promote the growth and survival of the culturedcluster of two or more blastomeres is supplemented with ACTH.

In certain aspects, the invention provides a method of producing anembryonic stem cell, comprising the step of culturing a blastomere inembryo medium wherein the blastomere is obtained from an embryo andwherein the embryo remains viable. The method comprises the step ofdirectly or indirectly contacting the cultured blastomere with embryonicstem cells with the proviso that the contacting is not carried out byaggregating the cultured blastomere with embryonic stem cells as hadbeen previously described in Chung et al., Nature (2006) 439:216-9. Forexample, the cultured blastomere can be cultured in a microdrop and theembryonic stem cells are cultured in separate microdrops. Each microdropcan contain a single blastomere or multiple blastomeres. The microdropcontaining the blastomere(s) can be connected to or merged with themicrodrop containing the embryonic stem cells using any means known tothose of ordinary skill in the art. In one embodiment, the connecting ormerging of the two microdrops is carried out by dragging a manipulationpipette between two drops under light mineral oil such as paraffin oilor Squibb's oil.

The method of producing an ES or ED cell may also be used to culturesingle cells from morula stage embryo, inner cell mass, or embryonicdisk, or single embryonic cell or single embryonic germ cell.

In one embodiment, the blastomere is obtained from an embryo prior tocompaction of the morula. The entire one cell zygote may be used, thoughthis does not provide the advantage of circumventing the ethicalobjections some people have to the use of the entire embryo in cell linederivation. Therefore, the preferred method is the use of a donor cellfrom an embryo between the two cell stage and the blastocyst stage ofdevelopment. In another embodiment, the embryo is obtained beforeformation of the blastocoel. The blastomere may be obtained by partialor complete removal of the zona pellucida surrounding the embryo. Thebiopsied embryo may be implanted or cryopreserved. The initial embryomay have been obtained from oocytes fertilized in vivo or in vitro andmay or may not have been previously cryopreserved.

The culture of the blastomere obtained from the embryo is directly orindirectly contacted with cultures of any suitable cell to produce an EScell line or to produce ED cells, or both. Such suitable cells include,but are not limited to, embryonic stem cells, such as from alreadyestablished lines, embryo carcinoma cells, embryonic fibroblastsincluding murine embryonic cells, other embryo-like cells, cells ofembryonic origin or cells derived from embryos, many of which are knownin the art and available from the American Type Culture Collection,Manassas, Va. 20110-2209, USA, and other sources.

The blastomere may also be cultured with factors that inhibitdifferentiation of the ES cell derived from the blastomere. Such factorsinclude, without limitation, any factor that blocks or modifies theexpression of genes involved in trophoblast development. In oneembodiment, the blastomere is cultured in the presence of heparin. Inanother embodiment, Oct-4 is introduced into the blastomere oralternatively, expression of endogenous Oct-4 is induced in theblastomere.

In another embodiment, a blastomere obtained from an embryo undergoescell division and one progeny cell is used for genetic testing andanother progeny cell is used to produce an ES cell or cell line.

The ES cells produced from the blastomere may be pluripotent or by somedefinitions totipotent. The degree of pluripotency of the ES cell may bedetermined by assaying for ES cell marker proteins. Such proteins areknown in the art and include Oct-4, SSEA-3, SSEA-4, TRA-1-60, TRA-1-81,and alkaline phosphatase.

The present method of producing an ES or ED cell may be performed onhuman embryos as well as non-human embryos, e.g., non-human mammalianembryos, other primate embryos, horse embryos, avian embryos or dogembryos.

In another embodiment, the present invention provides a method forproducing differentiated progenitor cells, comprising:

-   -   (i) obtaining blastomere cells from an embryo that has at least        one cell, preferable two cells, but has not yet developed to the        stage of a compacted morula; and    -   (ii) inducing differentiation of the blastomere cells to produce        differentiated progenitor cells without producing an embryonic        stem cell line.

The differentiated progenitor cells can be used to derive cells, tissuesand/or organs which are advantageously used in the area of cell, tissue,and/or organ transplantation.

Another aspect of the present invention provides a method for producingdifferentiated progenitor cells, comprising:

-   -   (i) obtaining blastomere cells from an embryo that has at least        one cell, preferably two cells, but has not yet developed to the        stage of a compacted morula;    -   (ii) culturing the blastomere to obtain an aggregate of more        than one cell; and    -   (iii) inducing differentiation of the blastomere-derived cells        to produce differentiated progenitor cells without producing an        embryonic stem cell line.        The differentiated progenitor cells can be used to derive cells,        tissues and/or organs which are advantageously used in the area        of cell, tissue, and/or organ transplantation.

The present invention also provides methods of differentiating the ES orED cells produced by the methods of the invention. The ES or ED cellsmay be differentiated into any cell type including those of mesodermal,endodermal and ectodermal origin. For example, the blastomere may alsobe cultured with factors that induce differentiation of the ES or EDcell. In one embodiment, the blastomere is cultured in the presence ofFGF-4. In some embodiments the ES or ED cell derived from the blastomereis directly differentiated into the desired cell or tissue type withoutthe intermediate state of propagating the undifferentiated ES cells asundifferentiated cell lines.

Also contemplated are methods of differentiating the blastomere obtainedfrom an embryo into a differentiated cell type, e.g., mesoderm, endodermor ectoderm without first producing an ES cell from the blastomere.

The invention also encompasses the ES or ED cells produced by themethods of this invention, ES cell lines derived from the ES cells, EDcell lines derived from the ED cells, as well as differentiated cellsderived from the ES or ED cells or cell lines.

The ES or ED cells provided by this invention or cells derived from theES or ED cells are useful for treating disorders amenable to celltherapy. Pharmaceutical compositions comprising these cells togetherwith a pharmaceutically acceptable medium or carrier are also provided.

The TS cell produced by the methods of the invention may express a TScell marker, e.g., fibroblast growth factor receptor 2 (fgfr2),placental lactogen 1 (PL-1) and eomesodermin (mEomes). The TS cell mayalso lack expression of Oct-4 or α-fetoprotein.

The TS cell may also be cultured to produce a TS cell line ordifferentiated cell line.

This invention also provides novel methods of isolating blastomeres froman embryo. The method comprises the step of immobilizing the embryo andtapping the immobilized embryo until a blastomere is isolated. Theembryo can be immobilized by any means known to those of skill in theart. In one embodiment, the embryo is immobilized using a micropipetteand the micropipette holder is tapped to isolate the blastomere. Inanother embodiment, the embryo is cultured in medium that is calcium andmagnesium free. The embryo may be from the 2-cell stage to the 16 cellstage. In one embodiment, the embryo is from the 4 cell stage to the 10cell stage. In another embodiment the embryo is a 6-8 cell stage embryo.In yet another embodiment, the embryo is an 8-10 cell stage embryo.

In certain embodiments, the invention provides the use of the cellculture as described above in the manufacture of a medicament to treat acondition in a patient in need thereof.

In certain embodiments, the invention provides the use of thepharmaceutical preparation as described above in the manufacture of amedicament to treat a condition in a patient in need thereof.

In certain embodiments of any of the foregoing, a blastomere is obtainedfrom a mammalian embryo. Exemplary mammalian embryos include, but arenot limited to, mice embryos, rat embryos, dog embryos, cat embryos,rabbit embryos, cow embryos, sheep embryos, pig embryos, non-humanprimate embryos, and human embryos. In certain embodiments of any of theforegoing, a blastomere is obtained from a human embryo and the methodcomprises producing ES cells, ES cell lines, TS cells, TS cell lines, EDcells, or any partially or terminally differentiated cell type thereof.

In certain embodiments of any of the foregoing, a cluster of two or moreblastomeres may be directly or indirectly contacted with embryonic orfetal cells. In certain other embodiments, the embryonic or fetal cellsare from the same species as the blastomere. In certain embodiments, theembryonic or fetal cells are from a different species as the blastomere.In certain embodiments, the embryonic or fetal cells are human cells.Regardless of the particular embryonic or fetal cells used, the cellsmay be grown in the presence or absence of feeder layers.

In certain embodiments, contact with embryonic or fetal cells is notnecessary. In certain embodiments, a cluster of two or more blastomeresis cultured in the presence of one or more factors sufficient to promotefurther survival and/or maturation so that ES cells, TS cells, and/or EDcells can be produced from a blastomere.

The invention contemplates various methods for producing ES cells, TScells, and/or ED cells from a blastomere obtained from an embryo. Incertain embodiments, a culture produces a combination of cells types. Ifdesired, one or more particular cell types in the culture can beseparated and further cultured to produce a substantially purifiedpopulation of cells or a cell line.

The invention contemplates combinations of any of the foregoing orfollowing aspects and embodiments of the invention.

BRIEF DESCRIPTION OF THE FIGURES

FIG. 1A shows a biopsy of a single human blastomere. FIGS. 1B-C showblastomere-derived outgrowths (see arrows) close to a colony ofGFP-positive human embryonic stem (hES) cells. FIG. 1D illustrates themorphology of hES cell colonies. FIG. 1E shows Oct-4 staining in hEScells. FIGS. 1F-H show immunofluorescence analysis of molecular markersof primitive endoderm (α-feto protein, FIG. 1F), mesoderm (smooth muscleactin, FIG. 1G) and ectoderm (tubulin β III, FIG. 1H). (Scale bar: 50 μmfor FIG. 1A; 200 μm for FIG. 1B-H).

FIG. 2(a) shows a biopsy of a single blastomere; 2(b) shows thedevelopment of a blastomere-biopsied embryo into a hatching blastocyst;2(c) and (d) shows blastomere-derived outgrowth (arrows) close to acolony of GFP-positive hES cells; 2(e) shows the morphology ofblastomere-derived hES cell colonies.

FIG. 3 shows the results of characterizing human ES cells derived fromsingle blastomeres. FIG. 3(a) through 3(g) show immunofluorescencestaining for molecular markers for pluripotency: (a) Oct-4 andcorresponding DAPI staining (b), (c) TRA-1-60, (d) TRA-1-81, (e) SSEA-3,(f) SSEA-4, (g) alkaline phosphatase (Scale bar, 200 um). FIG. 3(h)shows representative chromosome spreads of the twosingle-blastomere-derived hES cell lines (MA01 and MA09).

FIG. 4 shows the in vitro differentiation of single blastomere-derivedhuman ES cells into all three germ layers. FIG. 4(a) shows teratomaformation after transplantation of the human ES cells under the kidneycapsule of NOD-SCID mice for seven weeks. Inserts show enlargement ofadjacent sections; left, neural tissue stained for Nestin (ectoderm);center, alpha smooth muscle actin (mesoderm); right, intestine stainedfor cdx2 (endoderm) to confirm presence of all three germ layers. FIG.4(b) through 4(d) shows immunofluorescence analysis of molecular markersof (b) ectoderm (tubulin β III), (c) mesoderm (smooth muscle actin), and(d) primitive endoderm (α-feto protein). FIG. 4(e) through (i) showresults of in vitro differentiation of single blastomere-derived humanES cells into cells of specific therapeutic interest; (e) endothelialcells plated on Matrigel showing formation of typical capillarytube-like structures, (f) Ac-LDL uptake by endothelial cells, (g) and(h) retinal pigment epithelium (RPE) showing pigmented phenotype andtypical “cobblestone” morphology (g) and bestrophin staining (h). FIG.4(i) shows results of RT-PCR confirming the presence of PEDF (lanes 1and 2) and RPE65 (lanes 3 and 4) in the human ES cell that wasdifferentiated into RPE cells (Lanes 1 and 3: hES-derived RPE cells;lanes 2 and 4: fetal RPE controls).

FIG. 5 shows microsatellite and PCR analysis of singleblastomere-derived human ES cell lines (MA01 and MA09) and the cell line(WA01) used for co-culture. FIG. 5(a), (b) and (c) show results of PCRto detect the presence of amelogenin, SRY and eGFP, respectively. FIG.5(d) shows the results of the microsatellite analysis.

FIG. 6 (a-i) shows photographs of different morphologies ofembryo-derived directly-differentiated cells originating from isolatedblastomeres in the absence of such blastomeres leading to hES celllines.

FIG. 7 shows the results of RT-PCR analysis of the expression of markersof pluripotency in single blastomere-derived hES cells lines. Top panel,Oct-4; center panel, nanog; bottom panel, GAPDH. Lane 1, no template;lane 2, negative control (MEFs); lane 3, MA01; lane 4, MA09; lane 5,WA01.

FIG. 8 shows the results of RT-PCR analysis for markers of RPE insingle-blastomere-derived RPE. For each gel: lane 1, negative control(undifferentiated hES cells, line WA09); lane 2, RPE from hES cells.

DETAILED DESCRIPTION OF THE INVENTION

Previous attempts to induce isolated human blastomeres to proliferateinto pluripotent embryonic stem cells have failed (Geber S. et al., Hum.Reprod. 10:1492-1496 (1995)). The present invention is based, in part,on the discovery that stem cells can be generated from embryos withoutaffecting viability of the embryo using novel methods disclosed herein.In one embodiment, these methods utilize in vitro techniques related tothose currently used in pre-implantation genetic diagnosis (PGD) toisolate single blastomeres from embryos without destroying the embryosor otherwise significantly altering their viability. As demonstratedherein, pluripotent human embryonic stem (hES) cells and cell lines canbe generated from a single blastomere removed from an embryo withoutinterfering with the embryo's normal development to birth.

The methods described herein have numerous important uses that willadvance the field of stem cell research and developmental biology. EScells, ES cell lines, TS cells and cell lines, and cells differentiatedtherefrom can be used to study basic developmental biology, and can beused therapeutically in the treatment of numerous diseases andconditions. Additionally, these cells can be used in screening assays toidentify factors and conditions that can be used to modulate the growth,differentiation, survival, or migration of these cells. Identifiedagents can be used to regulate cell behavior in vitro and in vivo, andmay form the basis of cellular or cell-free therapies.

In order that the invention herein described may be fully understood,the following detailed description is set forth.

Unless defined otherwise, all technical and scientific terms used hereinhave the same meaning as those commonly understood by one of ordinaryskill in the art to which this invention belongs. Although methods andmaterials similar or equivalent to those described herein can be used inthe invention or testing of the present invention, suitable methods andmaterials are described below. The materials, methods and examples areillustrative only, and are not intended to be limiting.

All publications, patents, patent publications and applications andother documents mentioned herein are incorporated by reference in theirentirety.

Throughout this specification, the word “comprise” or variations such as“comprises” or “comprising” will be understood to imply the inclusion ofa stated integer or groups of integers but not the exclusion of anyother integer or group of integers.

The articles “a” and “an” are used herein to refer to one or to morethan one (i.e., to at least one) of the grammatical object of thearticle. By way of example, “an element” means one element or more thanone element.

The term “blastomere” is used throughout to refer to at least oneblastomere (e.g., 1, 2, 3, 4, etc) obtained from an embryo. The term“cluster of two or more blastomeres” is used interchangeably with“blastomere-derived outgrowths” to refer to the cells generated duringthe in vitro culture of a blastomere. For example, after a blastomere isobtained from an embryo and initially cultured, it generally divides atleast once to produce a cluster of two or more blastomeres (also knownas a blastomere-derived outgrowth). The cluster can be further culturedwith embryonic or fetal cells. Ultimately, the blastomere-derivedoutgrowths will continue to divide. From these structures, ES cells, TScells, and partially differentiated cell types will develop over thecourse of the culture method.

As summarized above, the present invention provides methods for derivingES cells, ES cell lines, and differentiated cell types from singleblastomeres of an early stage embryo without necessarily destroying theembryo. Various features of the method a described in detail below. Allof the combinations of the various aspects and embodiments of theinvention detailed above and below are contemplated.

Removal of the Blastomere

The blastomere may be removed from an embryo at various developmentalstages prior to implantation including but not limited to: beforecompaction of the morula, during compaction of the morula, right aftercompaction of the morula, before formation of the blastocoel or duringthe blastocyst stage. In certain embodiments, a blastomere (oneblastomere, two blastomeres, or more than two blastomeres) is removedfrom an embryo at the 4-16 cell stage, or at the 4-10 cell stage, or atthe 4-8 cell stage.

In one embodiment the invention provides methods for biopsy of ablastocyst which will produce embryonic stem cells, and the remainder ofthe blastocyst is implanted and results in a pregnancy and later in alive birth. In an example of this: the zona pellucida is removed fromthe blastocyst by any means known to those of ordinary skill in the artand then the blastocyst is biopsied.

In another embodiment the controversies associated with the derivationof human ES cells are circumvented by using a technique similar to thatused in preimplantation genetic diagnosis (PGD) where a singleblastomere is removed from the embryo. In one embodiment, the singleblastomere is removed before the compaction of the morula. The biopsiedblastomere could be allowed to undergo cell division and one progenycell is used for genetic testing and the remaining cells are used togenerate human stem cells. The biopsied embryo may also be implanted atthe blastocyst stage or frozen for implantation at a later time.

In certain embodiments, biopsy (e.g., removal of a blastomere from anembryo) consists of two stages. The first is to make a hole in, or insome instances fully remove, the zone pellucida that surrounds theembryo. Once the hole is made, the cells (preferably one or two) maythen be removed from the human embryo. In certain preferred embodiments,the method involves removing or generating an extraction hole in thezona pellucida, and can be carried out by one or more techniques such asphysical manipulation, chemical treatment and enzymatic digestion.Exemplary techniques that could be used include:

-   -   Partial zone dissection (PZD:): partial dissection of the zona        pellucida, using a micro-pipette;    -   Zona drilling: chemical opening of the zona pellucida zone        through partial digestion with Tyrode acid;    -   Zona drilling: enzymatic opening of the zona pellucida zone        through partial digestion with pronase or other protease;    -   zona pellucida thinning: thinning of the zona pellucida with        Tyrode acid or laser;    -   Point-like opening of the zona pellucida with laser;    -   Point-like mechanical opening of the zona pellucida with Piezo        micro-manipulator.

To briefly illustrate one embodiment, the procedure is performed on 8-10cell stage embryos. The embryo is placed in a drop of biopsy mediumunder mineral oil by holding it with a holding pipette. The zonapellucida is locally digested, by releasing acidified Tyrode's solution(Sigma, St. Louis, Mo. 63178) through an assistant hatching pipette.Once the hole is made, cells (blastomeres) could be aspirated throughthe hole.

To illustrate another embodiment, the zona pellucida of the blastocystmay be at least partially digested by treatment with one or more enzymesor mixture of enzymes such as pronase. A brief pronase (Sigma) treatmentof blastocysts with an intact zona pellucida results in the removal ofthe zona. Other types of proteases with the same or similar proteaseactivity as pronase may also be used.

Single blastomeres may also be obtained by disaggregating zona-denudedembryos in Ca⁺⁺/Mg⁺⁺ free PBS.

This invention also provides a novel and more efficient method ofisolating single blastomeres. The embryo is immobilized and theimmobilized embryo is then tapped until a single blastomere is releasedfrom the blastocyst. This method is not limited to human embryos and canbe performed on embryos of other species including, without limitation,non-human embryos such as non-human mammals, mice, rabbits, pigs, cows,sheep, dogs and primates.

The embryo can be immobilized by any means known to those of skill inthe art. In one embodiment, the embryo is immobilized using amicropipette and the micropipette holder is tapped to isolate theblastomere. In another embodiment, the embryo is cultured in medium thatis calcium and magnesium free. The embryo may be from the 2-cell stageto the 16 cell stage. In one embodiment, the embryo is from the 4 cellstage to the 10 cell stage. In another embodiment the embryo is a 6-8cell stage embryo. In yet another embodiment, the embryo is an 8-10 cellstage embryo. In certain embodiments, tapping involves generating anamount of force sufficient to remove at least one blastomere withoutsubstantially decreasing the viability of the remainder of the embryo.Maintenance of viability can be shown, for example, by culturing theremaining embryo for at least one day and confirming that the remainingembryo can continue to divide in culture.

Any of the foregoing methods can be used to obtain a blastomere (oneblastomere or more than one blastomere) from an embryo. A particularmethod can be used alone or in combination with another method tofacilitate removal of a blastomere.

In certain embodiments, the embryo is a mammalian embryo. In certainembodiments, the mammalian embryo is a human embryo. Exemplary mammalsinclude, but are not limited to, mice, rats, rabbits, cows, dogs, cats,sheep, hamsters, pigs, non-human primates, and humans.

In certain embodiments of any of the foregoing, a blastomere is removedfrom an embryo without destroying the remainder of the embryo. Theremaining embryo (the embryo minus the removed blastomere) can becultured and/or cryopreserved. In certain embodiments, the remainingembryo is cultured for a time sufficient to confirm that the remainingembryo can continue to divide (e.g., is still viable), and then onceviability is confirmed, the remaining embryo is cryopreserved. Incertain other embodiments, the remaining embryo is immediatelycryopreserved.

In certain other embodiments, multiple blastomeres are removed from asingle embryo and the embryo is destroyed during or subsequent to theremoval of multiple blastomeres. Multiple blastomeres can be usedtogether in one experiment, for example, by aggregating multipleblastomeres during the initial blastomere culture. Alternatively,multiple blastomeres can be used in separate experiments in an effort tomaximize the number of lines or cell types than can be generated from asingle embryo.

Embryos from which a blastomere is obtained can be generated by sexualor asexual methods. In certain embodiments, the embryo is produced byfertilization of an egg with a sperm. In certain other embodiments, theembryo is produced by somatic cell nuclear transfer, parthenogenesis,androgenesis, or other asexual techniques. Note that embryos derivedfrom asexual techniques may not look identical to embryos generated byfertilization. However, despite any differences in appearance, the termembryo is intended to encompass the products of asexual reproduction andthe products of fertilization or other means of sexual reproduction.

Culturing the Blastomere and Production of ES Cells

Once removed from the embryo, the isolated blastomere(s) can beinitially cultured in any type of medium, e.g., embryo medium such asQuinn's cleavage medium (Cooper Surgical Inc. Cat #ART1529). Any mediumthat supports growth of an embryo can be used, including, withoutlimitation, any commercial formulations. As used herein, the term“embryo medium” is used to refer to a medium that promotes survival ofblastomeres (especially human blastomeres) in culture. In certainembodiments, the embryo medium is a medium containing less than 5 mMglucose. In certain embodiments, the embryo medium is a medium that hasan osmolarity of less that 310 mosm. In certain other embodiments, theembryo medium is a medium that contains less than 5 mM glucose and hasan osmolarity of less than 310 mosm. In certain embodiments, the mediumused to initially culture blastomeres has an osmolarity of less than 300mosm, less than 280 mosm, or less than 260 mosm, and optionally containsless than 5 mM glucose. In certain embodiments, the medium used toinitially culture blastomeres has an osmolarity about 260-280 mosm, andoptionally contains less than 5 mM glucose. Note that regardless of theosmolarity and particular concentration of glucose in the medium used toinitially culture the blastomeres, the medium may also be supplementedwith antibiotics, minerals, amino acids, and other factors typicallyfound in commercial media formulations.

The blastomeres may not initially grow well in standard ES cell medium.However, as described in detail herein, once the blastomeres have beencultured in the presence of certain embryonic or fetal cells and/orallowed to divide one or more times, the cluster of blastomeres canoptionally be cultured in ES cell medium, or may be slowly transferredfrom embryo medium to ES cell medium by gradually replacing the medium.As used herein, the term “ES cell medium” is used to refer to a mediumthat promotes maintenance of ES cells in culture and can be used toculture clusters of blastomeres as they continue to divide and produceES cells, ED cells, etc. Such a medium is at least somewhat optimizedfor ES cells. In certain embodiments, the ES cell medium contains atleast 5 mM glucose (relatively high glucose). In certain otherembodiments, the ES cell medium has an osmolarity of at least 310 mosm.In certain other embodiments, the medium contains at least 5 mM glucoseand has an osmolarity of at least 310 mosm. In certain embodiments, thismedium has an osmolarity of at least 320 mosm, or at least 330 mosm, andoptionally contains at least 5 mM glucose. In certain embodiments, thismedium has an osmolarity of about 310-340 mosm, and optionally containsat least 5 mM glucose. ES cell medium may also be supplemented withfactors known in the art to promote the growth of ES cells, and themedium may contain antibiotics, minerals, amino acids, and other factorstypically found in commercial media formulations.

In certain embodiments, a blastomere is obtained from a human or othermammalian embryo and cultured in embryo medium. Preferably, a blastomereis cultured in embryo medium for at least one day or until theblastomere divides at least once. However, a blastomere may be culturedin embryo medium for more than 1 day (at least 2, 3, 4 days, etc.)and/or the blastomere may be cultured in contact with embryonic or fetalcells before dividing to produce a cluster of blastoemre. When culturedin embryo medium, the blastomere may divide one or more times or producea cluster of two or more blastomeres. Further culturing of the clusterof blastomeres includes culturing the blastomere along with its progeny.In certain embodiments, the blastomere divides and the progeny arecultured as an aggregate.

In one embodiment, the blastomere can be cultured in a microdrop. Eachmicrodrop can contain a single blastomere or multiple blastomeres. Afterabout at least 1 day, at least 2-3 days, or at least 4 days, thecultured blastomeres may divide and form vesicles or aggregates. Thebenefit of culturing the blastomere prior to direct or indirect contactwith the embryonic cells is to prevent the embryonic cells fromovergrowing the blastomere.

After a blastomere is initially cultured to generate a cluster of two ormore blastomeres, the cultured cluster of two or more blastomeres iscontacted directly or indirectly with embryonic or fetal cells, oralternatively with a medium that promotes further maturation of theblastomeres in the absence of embryonic or fetal cells. Such mediumincludes medium conditioned with embryonic or fetal cells (conditionedmedium) or medium supplemented with growth factors or cytokines thatpromote maturation of the blastomeres. In certain embodiments, themedium is supplemented with ACTH (adrenocorticotropic hormone).

For embodiments in which direct or indirect culture with embryonic orfetal cells is used, the embryonic or fetal cells may be derived from,for example, a mammal. In certain embodiments, the embryonic or fetalcells are mouse or human cells. Exemplary embryonic or fetal cellsinclude, but are not limited to, embryonic stem (ES) cells (whetherderived from blastocysts, blastomeres, or by other methods, and whetherderived using somatic cell nuclear transfer or other asexualreproduction), embryonic germ cells, embryonic carcinoma cells,placental cells, trophoblasts/trophectoderm cells, trophoblast stemcells, primordial germ cells embryonic germ cells, amniotic fluid cells,amniotic stem cells, placental cells, placental stem cells, andumbilical cord cells. In certain embodiments in which blastomeres aredirectly or indirectly contacted with embryonic or fetal cells, themedium in which the blastomeres are cultured is further supplementedwith ACTH or other growth factors or cytokines that promote maturationof the blastomeres.

When used, the embryonic or fetal cells, may be grown in the presence orabsence of a feeder layer of cells. Feeder cells may be used to helpmaintain the embryonic or fetal cells and to prevent theirdifferentiation. The specific feeder cell may be chosen based on theparticular embryonic or fetal cell used. Exemplary feeder cells include,but are not limited to, fibroblast feeder cells. Such fibroblast feedercells may be derived from the same species as the embryonic or fetalcells or they may be derived from a different species. Similarly, thefeeder cells and the embryonic or fetal cells may be derived from thesame species as the blastomere or from a different species. In certainembodiments, the feeder cells are irradiated or otherwise treated toprevent overgrowth relative to the embryonic or fetal cells. Exemplaryfeeder cells include, but are not limited to, mouse embryonicfibroblasts (MEF cells), human embryonic fibroblasts, human foreskinfibroblasts, human skin fibroblasts, human endometrial fibroblasts,human oviductal fibroblasts, and placental cells. Similar cell typesderived from other animals (mammals, chickens, etc) are alsocontemplated.

In one embodiment, the feeder and/or embryonic cells are human cellsthat are autologous cells derived from the same embryo as theblastomere.

The embryonic or fetal cells are grown in ES cell medium or any mediumthat supports growth of the embryonic or fetal cells, e.g., KnockoutDMEM (Invitrogen Cat # 10829-018). Exemplary embryonic or fetal cellsinclude, but are not limited to, embryonic stem cells, such as fromalready established lines, embryo carcinoma cells, murine embryonicfibroblasts, other embryo-like cells, cells of embryonic origin or cellsderived from embryos, many of which are known in the art and availablefrom the American Type Culture Collection, Manassas, Va. 20110-2209,USA, and other sources.

The embryonic or fetal cells may be added directly to the culturedblastomeres or may be grown in close proximity to, but not in directcontact with, the cultured blastomere(s). Various direct and indirectco-culture systems are possible to facilitate providing the culturedblastomeres with factors or signals from the embryonic or fetal cells.As used herein, “contacting the cultured cluster of two or moreblastomeres” refers to any method of direct or indirect contact orco-culture.

In certain embodiments, contacting the cluster of two or more blastomerecomprises aggregating blastomere clusters with embryonic or fetal cells.In certain other embodiments, contacting comprises co-culturing thecluster of two or mores blastomeres so that the cells are in directcontact with the embryonic or fetal cells but are not aggregated tothem. In other embodiments, contacting comprises co-culturing thecluster of two or more blastomeres with the embryonic or fetal cells sothat the cells are in indirect contact, for example, maintained in thesame culture vessel but without direct contact of the cells ormaintained as contiguous microdrops.

In certain embodiments, the method comprises the step of directly orindirectly contacting the cultured cluster of two or more blastomere(s)with embryonic or fetal cells, with the proviso that the contacting isnot carried out by aggregating the cultured blastomere with embryoniccells as described in Chung et al., Nature (2006) 439:216-9.Alternatively, the culture of blastomere(s) and the culture of embryonicor fetal cells are indirectly connected or merged. This can be achievedby any method known in the art including, for example, dragging amanipulation pipette between two drops under light mineral oil such asCooper Surgical ACT# ART4008, paraffin oil or Squibb's oil. Theconnections can be made by using a glass capillary or similar device.Such indirect connections between the cultured blastomere and theembryonic cells allows gradual mixing of the embryo medium (in which theblastomere is cultured) and the ES cell medium (in which the humanembryonic cells are grown). In another embodiment, the blastomere(s) maybe co-cultured with the remaining embryo. For example, the blastomere isco-cultured with the remaining embryo in a microdroplet culture systemor other culture system known in the art, which does not permitcell-cell contact but could permit cell-secreted factor and/orcell-matrix contact. The volume of the microdrop may be reduced, e.g.,from 50 microliters to about 5 microliters to intensify the signal. Inanother embodiment the embryonic cells may be from a species other thanhuman, e.g., non-human primate or mouse.

In certain embodiments, the particular media formulations used toculture a blastomere, a cluster of two or more blastomeres, andembryonic or fetal cells may vary slightly depending on the species.Additionally, whether initial blastomere culture benefits from a mediaformulation different from that used to culture the clusters ofblastomeres or the embryonic cells may also vary slightly depending onthe species.

In certain embodiments, the medium used to separately culture ablastomere and the medium used to culture embryonic or fetal cells isnot necessarily the same. In embodiments for which the media differ,there may be a period where the blastomere or cluster of blastomeres isbeing initially exposed to a medium that differs from the medium inwhich the blastomere was initially cultured (e.g., the cells will beslowly exposed to the medium in which the embryonic or fetal cells werecultured). In such embodiments, the cluster of two or more blastomeres,which has now divided multiple times to give rise to a cluster of cellsand cell outgrowths, can gradually be transferred (for example byexchanging the medium) and cultured in medium having the properties ofES cell medium.

After about 3-4 days, the blastomere(s) exhibit properties of ES cells.Specifically, as the cells continue to divide and the blastomere progenycluster, various cell types emerge and can be identified phenotypically.Amongst the emerging cell types are trophectoderm-like cells, ES cells,and partially or terminally differentiated ED cells. As such, thesemethods can be used to produce ES cells, TS or other trophectodermcells, or ED cells. While not wishing to be bound by any particulartheory, it is believed that over a period of days or weeks the culturedblastomeres exhibit ES cell growth perhaps as a result of factorssecreted by the embryonic or fetal cells or by the extracellular matrix.Further, the dividing cluster of blastomere progeny resemble, in somerespects, the changes observed during development of the preimplantationblastocyst. As such, the cell types emerging in these culturesrecapitulate to some extent the cell types observed when wholeblastocysts or ICMs are plated.

In certain embodiments, the blastomere culture conditions may includecontacting the cells with factors that can inhibit or otherwisepotentiate the differentiation of the cells, e.g., prevent thedifferentiation of the cells into non-ES cells, trophectoderm or othercell types. Such conditions can include contacting the cultured cellswith heparin or introducing Oct-4 into the cells (such as by includingOct-4 in the media) or activating endogenous Oct-4 in the cells. In yetanother embodiment, expression of cdx-2 is prevented by any means knownin the art including, without limitation, introducing CDX-2 RNAi intoblastomeres, thereby inhibiting differentiation of the blastomere intoTS cells.

As detailed above, the invention provides methodologies for producing EScells, ED cells, and TS cells from a blastomere obtained from an embryo.This approach can be used to generate ES cells, ED cell, and TS cells,as well as cell line without necessarily destroying the embryo fromwhich the blastomere is obtained.

Culturing the Blastomere and Production of ED Cells

In the past, long-term culture of inner cell mass cells was used toproduce embryonic stem cell lines. Subsequently, the embryonic stemcells were cultured and conditionally genetically-modified, and inducedto differentiate in order to produce cells for therapy. U.S. patentapplication Ser. No. 11/025,893 (published as US 2005/0265976A1),incorporated herein in its entirety, describes a method of producingdifferentiated progenitor cells from inner cell mass cells ormorula-derived cells by directly inducing the differentiation of thosecells without producing an embryonic stem cell line and the use of saiddifferentiated cells, tissues, and organs in transplantation therapy.Because these cells are derived from the cells of the embryo but notfrom an ES cell line, we designate such cells as embryo-derived (ED)cells. Blastomere-derived ED cells have broader differentiationpotential than human ES cells produced using methods known in the artbecause the ED cells can be readily differentiated into germ-line cellsusing techniques known in the art, e.g. using methods to differentiatemurine ES cell lines into germ-line cells. In contrast, human ES celllines derived from inner mass cells are not expected to be capable ofdifferentiation into germ-line cells. This phenomenon has been observedin ES cells derived from inner mass cells in animal such as pigs, cows,chickens and rats and is likely due to the fact that germ-line is one ofthe first cell lineages to branch out in differentiation.

In some of the methods of the present invention, blastomeres fromembryos with at least two cells, and before the embryo enters the stageof development of a compacting morula are induced to directlydifferentiate into differentiated progenitor cells which are then usedfor cell therapy and for the generation of cells, tissues, and organsfor transplantation. If desired, genetic modifications can beintroduced, for example, into somatic cells prior to nuclear transfer toproduce a morula or blastocyst or into somatic cells prior to thereprogramming of said somatic cell into undifferentiated cells throughthe juxtaposition of the DNA of said somatic cell with factors capableof reprogramming said somatic cells or into ES cell lines made usingthese methods. See U.S. patent application Ser. No. 10/831,599 publishedas US 2004199935, PCT/US06/30632 filed Aug. 3, 2006, and U.S.Provisional Patent Application Nos. 60/705,625, 60/729,173 and60/818,813, the disclosure of which are incorporated herein by referencein their entirety. Thus, the differentiated progenitor cells of thepresent invention do not possess the pluripotency of an embryonic stemcell, or an embryonic germ cell, and are, in essence, tissue-specificpartially or fully differentiated cells. These differentiated progenitorcells may give rise to cells from any of three embryonic germ layers,i.e., endoderm, mesoderm, and ectoderm. For example, the differentiatedprogenitor cells may differentiate into bone, cartilage, smooth muscle,dermis with a prenatal pattern of gene expression and capable ofpromoting scarless wound repair, and hematopoietic or hemangioblastcells (mesoderm), definitive endoderm, liver, primitive gut, pancreaticbeta cells, and respiratory epithelium (endoderm); or neurons, glialcells, hair follicles, or eye cells including retinal neurons andretinal pigment epithelium.

Furthermore, it is not necessary for the differentiated progenitor cellsof the present invention to express the catalytic component oftelomerase (TERT) and be immortal, or that the progenitor cells expresscell surface markers found on embryonic stem cells such as the cellsurface markers characteristic of primate embryonic stem cells: positivefor SSEA-3, SSEA-4, TRA-1-60, TRA-1-81, alkaline phosphatase activity,and negative for SSEA-1. Moreover, the differentiated progenitor cellsof the present invention are distinct from embryoid bodies, i.e.,embryoid bodies are derived from embryonic stem cells whereas thedifferentiated stem cells of the present invention are derived fromblastomeres.

Preferably, the differentiated cells of the present invention areproduced by culturing blastomere-derived cells in the absence ofembryonic stem cells. Growth of undifferentiated embryonic stem cellscan be prevented, for example, by culturing blastomeres in the presenceof differentiation-inducing agents or by introducing geneticmodifications into the cells such that the growth of embryonic stemcells is prevented.

Any vertebrate embryo may be used as a source of blastomeres or cellsequivalent in development to a mammalian blastomere. Human blastomeres,in particular, have important utility in the generation of humancell-based therapies. The original embryo may have been produced by invitro-fertilization, derived by fertilization within the reproductivetract by normal sexual reproduction, artificial insemination, or gameteintrafallopian transfer (GIFT), and subsequently retrieved, derived bysomatic cell nuclear transfer.

Differentiation

Methods for isolating blastomeres have already been described herein.Isolated blastomeres can be induced directly or via ES cells or celllines to differentiate in the presence of differentiation-inducingconditions including various combinations of growth factors, sera,hormones, extracellular matrices useful in making the particular desireddifferentiated cell type as known in the art (see Table 2 for list ofexemplary molecules), or as disclosed in the pending applicationsPCT/US2006/013573 filed Apr. 11, 2006, U.S. Application No. 60/835,779,filed Aug. 3, 2006, 60/792,224 filed Apr. 14, 2006, 60/801,993 filed May19, 2006, PCT/US2006/013519 filed Apr. 11, 2006, U.S. application Ser.No. 11/025,893 (published as US 20050265976), WO2005/070011 publishedAug. 4, 2005, and WO 2006/080952 published Aug. 3, 2006, the disclosureof which are incorporated herein by reference. For example, blastomeresor ES cells may be cultured on various inducer cell types such as thoseisolated as single cell-derived populations of cells, or on particularextracellular matrix components and other differentiation-inducingfactors such as factors or combinations of factors shown in Table 2below. TABLE 2 Culture Variables EGF Ligands 1) Amphiregulin 2)Betacellulin 3) EGF 4) Epigen 5) Epiregulin 6) HB-EGF 7) Neuregulin-3 8)NRG1 isoform GGF2 9) NRG1 Isoform SMDF 10) NRG1-alpha/HRG1-alpha 11)TGF-alpha 12) TMEFF1/Tomoregulin-1 13) TMEFF2 14) EGF Ligands pooled(1-13 above) EGF R/ErbB Receptor Family 15) EGF Receptor 16) ErbB2 17)ErbB3 18) ErbB4 19) EGF/ErbB Receptors pooled (15-18 above) FGF Ligands20) FGF acidic 21) FGF basic 22) FGF-3 23) FGF-4 24) FGF-5 25) FGF-6 26)KGF/FGF-7 27) FGF-8 28) FGF-9 29) FGF-10 30) FGF-11 31) FGF-12 32)FGF-13 33) FGF-14 34) FGF-15 35) FGF-16 36) FGF-17 37) FGF-18 38) FGF-1939) FGF-20 40) FGF-21 41) FGF-22 42) FGF-23 43) FGF Ligands pooled(20-38 above) FGF Receptors 40) FGF R1 41) FGF R2 42) FGF R3 43) FGF R444) FGF R5 45) FGF Receptors pooled (40-44 above) FGF Regulators 46)FGF-BP Hedgehogs 47) Desert Hedgehog 48) Sonic Hedgehog 49) IndianHedgehog 50) Hedgehogs pooled (47-49 above) Hedgehog Regulators 51) Gas152) Hip 53) Hedgehog Regulators pooled (51-52 above) IGF Ligands 54)IGF-I 55) IGF-II 56) IGF Ligands pooled (54-55 above) IGF-I Receptor(CD221) 57) IGF-I R GF Binding Protein (IGFBP) Family 58) ALS 59 IGFBP-460) CTGF/CCN2 61) IGFBP-5 62) Endocan 63) IGFBP-6 64) IGFBP-1 65)IGFBP-rp1/IGFBP-7 66) IGFBP-2 67) NOV/CCN3 68) IGFBP-3 69) GF BindingProtein Family pooled (58-68 above) Receptor Tyrosine Kinases 70) Axl71) C1q R1/CD93 72) DDR1 73) Flt-3 74) DDR2 75) HGF R 76) Dtk 77) IGF-IIR 78) Eph 79) Insulin R/CD220 80) EphA1 81) M-CSF R 82) EphA2 83) Mer84) EphA3 85) MSP R/Ron 86) EphA4 87) MuSK 88) EphA5 89) PDGF R alpha90) EphA6 91) PDGF R beta 92) EphA7 93) Ret 94) EphA8 95) ROR1 96) EphB197) ROR2 98) EphB2 99) SCF R/c-kit 100) EphB3 101) Tie-1 102) EphB4 103)Tie-2 104) EphB6 105) TrkA 106) TrkB 107) TrkC 108) VEGF R1/Flt-1 109)VEGF R2/Flk-1 110) VEGF R3/Flt-4 111) Receptor Tyrosine Kinases pooled(70-110 above) Proteoglycans 112) Aggrecan 113) Lumican 114) Biglycan115) Mimecan 116) Decorin 117) NG2/MCSP 118) Endocan 119) Osteoadherin120) Endorepellin 121) Syndecan-1/CD138 122) Glypican 2 123) Syndecan-3124) Glypican 3 125) Testican 1/SPOCK1 126) Glypican 5 127) Testican2/SPOCK2 128) Glypican 6 129) Testican 3/SPOCK3 130) Heparan sulfateproteoglycan 131) Heparin 132) Chondroitin sulfate proteoglycan 133)Hyaluronic acid 134) Dermatan sulfate proteoglycan ProteoglycanRegulators 135) Arylsulfatase A/ARSA 136) HAPLN1 137) Exostosin-like 2138) HS6ST2 139) Exostosin-like 3 140) IDS 141) Proteoglycan Regulatorspooled (135-140 above) SCF, Flt-3 Ligand & M-CSF 142) Flt-3 143) M-CSF R144) Flt-3 Ligand 145) SCF 146) M-CSF 147) SCF R/c-kit 148) Pooledfactors (142-147 above) Activins 149) Activin A 150) Activin B 151)Activin AB 152) Activin C 153) Pooled Activins (149-152 above) BMPs(Bone Morphogenetic Proteins) 154) BMP-2 155) BMP-3 156) BMP-3b/GDF-10157) BMP-4 158) BMP-5 159) BMP-6 160) BMP-7 161) BMP-8 162)Decapentaplegic 163) Pooled BMPs (154-162 above) GDFs (GrowthDifferentiation Factors) 164) GDF-1 165) GDF-2 166) GDF-3 167) GDF-4168) GDF-5 169) GDF-6 170) GDF-7 171) GDF-8 172) GDF-9 173) GDF-10 174)GDF-11 175) GDF-12 176) GDF-13 177) GDF-14 178) GDF-15 179) GDFs pooled(164-178 above) GDNF Family Ligands 180) Artemin 181) Neurturin 182)GDNF 183) Persephin 184) GDNF Ligands pooled (180-183 above) TGF-beta185) TGF-beta 186) TGF-beta 1 187) TGF-beta 1.2 188) TGF-beta 2 189)TGF-beta 3 190) TGF-beta 4 191) TGF-beta 5 192) LAP (TGF-beta 1) 193)Latent TGF-beta 1 194) TGF-beta pooled (185-193 above) Other TGF-betaSuperfamily Ligands 195) Lefty 196) Nodal 197) MIS/AMH 198) OtherTGF-beta Ligands pooled (195-197 above) TGF-beta Superfamily Receptors199) Activin RIA/ALK-2 200) GFR alpha-1 201) Activin RIB/ALK-4 202) GFRalpha-2 203) Activin RIIA 204) GFR alpha-3 205) Activin RIIB 206) GFRalpha-4 207) ALK-1 208) MIS RII 209) ALK-7 210) Ret 211) BMPR-IA/ALK-3212) TGF-beta RI/ALK-5 213) BMPR-IB/ALK-6 214) TGF-beta RII 215) BMPR-II216) TGF-beta RIIb 217) Endoglin/CD105 218) TGF-beta RIII 219) TGF-betafamily receptors pooled (199-218 above) TGF-beta Superfamily Modulators220) Amnionless 221) GASP-2/WFIKKN 222) BAMBI/NMA 223) Gremlin 224)Caronte 225) NCAM-1/CD56 226) Cerberus 1 227) Noggin 228) Chordin 229)PRDC 230) Chordin-Like 1 231) Chordin-Like 2 232) Smad1 233) Smad4 234)Smad5 235) Smad7 236) Smad8 237) CRIM1 238) Cripto 239) Crossveinless-2240) Cryptic 241) SOST 242) DAN 243) Latent TGF-beta bp1 244)TMEFF1/Tomoregulin-1 245) FLRG 246) TMEFF2 247) Follistatin 248) TSG249) Follistatin-like 1 250) Vasorin 251) GASP-1/WFIKKNRP 252) TGFModulators pooled (220-251 above) VEGF/PDGF Family 253) Neuropilin-1254) PlGF 255) PlGF-2 256) Neuropilin-2 257) PDGF 258) VEGF R1/Flt-1259) PDGF R alpha 260) VEGF R2/Flk-1 261) PDGF R beta 262) VEGF R3/Flt-4263) PDGF-A 264) VEGF 265) PDGF-B 266) VEGF-B 267) PDGF-C 268) VEGF-C269) PDGF-D 270) VEGF-D 271) PDGF-AB 272) VEGF/PDGF Family pooled(253-271 above) Dickkopf Proteins & Wnt Inhibitors 273) Dkk-1 274) Dkk-2275) Dkk-3 276) Dkk-4 277) Soggy-1 278) WIF-1 279) Pooled factors(273-278 above) Frizzled & Related Proteins 280) Frizzled-1 281)Frizzled-2 282) Frizzled-3 283) Frizzled-4 284) Frizzled-5 285)Frizzled-6 286) Frizzled-7 287) Frizzled-8 288) Frizzled-9 289) sFRP-1290) sFRP-2 291) sFRP-3 292) sFRP-4 293) MFRP 294) Factors pooled(280-293 above) Wnt Ligands 295) Wnt-1 296) Wnt-2 297) Wnt-3 298) Wnt-3a299) Wnt-4 300) Wnt-5 301) Wnt-5a 302) Wnt-6 303) Wnt-7 304) Wnt-8 305)Wnt-8a 306) Wnt-9 307) Wnt-10a 308) Wnt-10b 309) Wnt-11 310 Wnt Ligandspooled (295-309 above) Other Wnt-related Molecules 311) beta-Catenin312) LRP-6 313) GSK-3 314) ROR1 315) Kremen-1 316) ROR2 317) Kremen-2318) WISP-1/CCN4 319) LRP-1 320) Pooled factors (311-319 above) OtherGrowth Factors 321) CTGF/CCN2 322) NOV/CCN3 323) EG-VEGF/PK1 324)Osteocrin 325) Hepassocin 326) PD-ECGF 327) HGF 328) Progranulin 329)beta-NGF 330) Thrombopoietin 331) Pooled factors (321-330 above) SteroidHormones 332) 17beta-Estradiol 333) Testosterone 334) Cortisone 335)Dexamethasone Extracellular/Memrane Proteins 336) Plasma Fibronectin337) Tissue Fibronectin 338) Fibronectin fragments 339) Collagen Type I(gelatin) 340) Collagen Type II 341) Collagen Type III 342) Tenascin343) Matrix Metalloproteinase 1 344) Matrix Metalloproteinase 2 345)Matrix Metalloproteinase 3 346) Matrix Metalloproteinase 4 347) MatrixMetalloproteinase 5 348) Matrix Metalloproteinase 6 349) MatrixMetalloproteinase 7 350) Matrix Metalloproteinase 8 351) MatrixMetalloproteinase 9 352) Matrix Metalloproteinase 10 353) MatrixMetalloproteinase 11 354) Matrix Metalloproteinase 12 355) MatrixMetalloproteinase 13 356) ADAM-1 357) ADAM-2 358) ADAM-3 359) ADAM-4360) ADAM-5 361) ADAM-6 362) ADAM-7 363) ADAM-8 364) ADAM-9 365) ADAM-10366) ADAM-11 367) ADAM-12 368) ADAM-13 369) ADAM-14 370) ADAM-15 371)ADAM-16 372) ADAM-17 373) ADAM-18 374) ADAM-19 375) ADAM-20 376) ADAM-21377) ADAM-22 378) ADAM-23 379) ADAM-24 380) ADAM-25 381) ADAM-26 382)ADAM-27 383) ADAM-28 384) ADAM-29 385) ADAM-30 386) ADAM-31 387) ADAM-32388) ADAM-33 389) ADAMTS-1 390) ADAMTS-2 391) ADAMTS-3 392) ADAMTS-4393) ADAMTS-5 394) ADAMTS-6 395) ADAMTS-7 396) ADAMTS-8 397) ADAMTS-9398) ADAMTS-10 399) ADAMTS-11 400) ADAMTS-12 401) ADAMTS-13 402)ADAMTS-14 403) ADAMTS-15 404) ADAMTS-16 405) ADAMTS-17 406) ADAMTS-18407) ADAMTS-19 408) ADAMTS-20 409) Arg-Gly-Asp 410) Arg-Gly-Asp-Ser 411)Arg-Gly-Asp-Ser-Pro-Ala-Ser- Ser-Lys-Pro 412) Arg-Gly-Glu-Ser 413)Arg-Phe-Asp-Ser 414) SPARC 415) Cys-Asp-Pro-Gly-Tyr-Ile-Gly- Ser-Arg416) Cys-Ser-Arg-Ala-Arg-Lys-Gln- Ala-Ala-Ser-Ile-Lys-Val-Ser-Ala-Asp-Arg 417) Elastin 418) Tropelastin 419) Gly-Arg-Gly-Asp-Ser-Pro-Lys 420)Gly-Arg-Gly-Asp-Thr-Pro 421) Laminin 422) Leu-Gly-Thr-Ile-Pro-Gly 423)Ser-Asp-Gly-Arg-Gly 424) Vitronectin 425) Superfibronectin 426)Thrombospondin 427) TIMP-1 428) TIMP-2 429) TIMP-3 430) TIMP-4 431)Fibromodulin 432) Flavoridin 433) Collagen IV 434) Collagen V 435)Collagen VI 436) Collagen VII 437) Collagen VIII 438) Collagen IX 439)Collagen X 440) Collagen XI 441) Collagen XII 442) Entactin 443)Fibrillin 444) Syndecan-1 445) Keratan sulfate proteoglycan AmbientOxygen 446) 0.1-0.5% Oxygen 447) 0.5-1% Oxygen 448) 1-2% Oxygen 449)2-5% Oxygen 450) 5-10% Oxygen 451) 10-20% Oxygen Animal Serum 452) 0.1%Bovine Serum 453) 0.5% Bovine Serum 454) 1.0% Bovine Serum 455) 5.0%Bovine Serum 456) 10% Bovine Serum 457) 20% Bovine Serum 458) 10% HorseSerum Interleukins 459) IL-1 460) IL-2 461) IL-3 462) IL-4 463) IL-5464) IL-6 465) IL-7 466) IL-8 467) IL-9 468) IL-10 469) IL-11 470) IL-12471) IL-13 472) IL-14 473) IL-15 474) IL-16 475) IL-17 476) IL-18Proteases 477) MMP-1 478) MMP-2 479) MMP-3 480) MMP-4 481) MMP-5 482)MMP-6 483) MMP-7 484) MMP-8 485) MMP-9 486) MMP-10 487) MMP-11 488)MMP-12 489) MMP-13 490) MMP-14 491) MMP-15 492) MMP-16 493) MMP-17 494)MMP-18 495) MMP-19 496) MMP-20 497) MMP-21 498) MMP-22 499) MMP-23 500)MMP-24 501) Cathepsin B 501) Cathepsin C 503) Cathepsin D 504) CathepsinG 505) Cathepsin H 506) Cathepsin L 507) Trypsin 508) Pepsin 509)Elastase 510) Carboxypeptidase A 511) Carboxypeptidase B 512)Carboxypeptidase G 513) Carboxypeptidase P 514) Carboxypeptidase W 515)Carboxypeptidase Y 516) Chymotrypsin 517) Plasminogen 518) Plasmin 519)u-type Plasminogen activator 520) t-type Plasminogen activator 521)Plasminogen activator inhibitor-1 522) Carboxypeptidase Z Amino Acids522) Alanine 523) Arginine 524) Asparagine 525) Aspartic acid 526)Cysteine 527) Glutamine 528) Glutamic acid 529) Glycine 530) Histidine531) Isoleucine 532) Leucine 533) Lysine 534) Methionine 535)Phenylalanine 536) Proline 537) Serine 538) Threonine 539) Tryptophan540) Tyrosine 541) Valine Prostaglandins 542) Prostaglandin A1 543)Prostaglandin A2 544) Prostaglandin B1 545) Prostaglandin B2 546)Prostaglandin D2 547) Prostaglandin E1 548) Prostaglandin E2 549)Prostaglandin F1alpha 550) Prostaglandin F2alpha 551) Prostaglandin H552) Prostaglandin I2 553) Prostaglandin J2 554) 6-Keto-ProstaglandinF1a 555) 16,16-Dimethyl-Prostaglandin E2 556) 15d-Prostaglandin J2 557)Prostaglandins pooled (542-556 above) Retinoid receptoragonists/Antagonists 558) Methoprene Acid 559) All trans retinoic acid560) 9-Cis Retinoic Acid 561) 13-Cis Retinoic Acid 562) Retinoid agonstspooled (558-561 above) 563) Retinoid antagonists 564) Retinoic acidreceptor isotype RARalpha 565) Retinoic acid receptor isotype RARbeta566) Retinoic acid receptor isotype RARgamma 567) Retinoic X receptorisotype RXRalpha 568) Retinoic X receptor isotype RXRbeta 569) RetinoicX receptor isotype RARgamma Miscellaneous Inducers 570) Plant lectins571) Bacterial lectins 572) forskolin 573) Phorbol myristate acetate574) Poly-D-lysine 575) 1,25-dihydroxyvitamin D 576) Inhibin 577)Heregulin 578) Glycogen 579) Progesterone 580) IL-1 581) Serotonin 582)Fibronectin - 45 kDa Fragment 583) Fibronectin - 70 kDa Fragment 584)glucose 585) beta mercaptoethanol 586) heparinase 587) pituitary extract588) chorionic gonadotropin 589) adrenocorticotropic hormone 590)thyroxin 591) Bombesin 592) Neuromedin B 593) Gastrin-Releasing Peptide594) Epinephrine 595) Isoproterenol 596) Ethanol 597) DHEA 598)Nicotinic Acid 599) NADH 600) Oxytocin 601) Vasopressin 602) Vasotocin603) Angiotensin I 604) Angiotensin II 605) Angiotensin I ConvertingEnzyme 606) Angiotensin I Converting Enzyme Inhibitor 607)Chondroitinase AB 608) Chondroitinase C 609) Brain natriuretic peptide610) Calcitonin 611) Calcium ionophore I 612) Calcium ionophore II 613)Calcium ionophore III 614) Calcium ionophore IV 615) Bradykinin 616)Albumin 617) Plasmonate 618) LIF 619) PARP inhibitors 620)Lysophosphatidic acid 621) (R)-METHANANDAMIDE 622) 1,25-DIHYDROXYVITAMIND3 623) 1,2-DIDECANOYL-GLYCEROL (10:0) 624) 1,2-DIOCTANOYL-SN- GLYCEROL625) 1,2-DIOLEOYL-GLYCEROL (18:1) 626) 10-hydroxycamptothecin 627)11,12- EPOXYEICOSATRIENOIC ACID 628) 12(R)-HETE 629) 12(S)-HETE 630)12(S)-HPETE 631) 12-METHOXYDODECANOIC ACID 632) 13(S)-HODE 633)13(S)-HPODE 634) 13,14-DIHYDRO-PGE1 635) 13-KETOOCTADECADIENOIC ACID636) 14,15- EPOXYEICOSATRIENOIC ACID 637) 1400W 638) 15(S)-HETE 639)15(S)-HPETE 640) 15- KETOEICOSATETRAENOIC ACID 641)17-Allylamino-geldanamycin 642) 17-OCTADECYNOIC ACID 643)17-PHENYL-TRINOR-PGE2 644) 1-ACYL-PAF 645) 1-HEXADECYL-2-ARACHIDONOYL-522) 646) GLYCEROL 647) 1-HEXADECYL-2- METHYLGLYCERO-3 PC648) 1-HEXADECYL-2-O-ACETYL- GLYCEROL 649) 1-HEXADECYL-2-O-METHYL-GLYCEROL 650) 1-OCTADECYL-2- METHYLGLYCERO-3 PC 651) 1-OLEOYL-2-ACETYL-GLYCEROL 652) 1-STEAROYL-2-LINOLEOYL- GLYCEROL 653) 1-STEAROYL-2-ARACHIDONOYL-GLYCEROL 654) 2,5-ditertbutylhydroquinone 655)24(S)-hydroxycholesterol 656) 24,25-DIHYDROXYVITAMIN D3 657)25-HYDROXYVITAMIN D3 658) 2- ARACHIDONOYLGLYCEROL 659) 2-FLUOROPALMITICACID 660) 2-HYDROXYMYRISTIC ACID 661) 2-methoxyantimycin A3 662)3,4-dichloroisocoumarin 663) granzyme B inhibitor 664) 4-AMINOPYRIDINE665) 4- HYDROXYPHENYLRETINAMIDE 666) 4-OXATETRADECANOIC ACID 667)5(S)-HETE 668) 5(S)-HPETE 669) 5,6-EPOXYEICOSATRIENOIC ACID 670)5,8,11,14- EICOSATETRAYNOIC ACID 671) 5,8,11-EICOSATRIYNOIC ACID 672)5-HYDROXYDECANOATE 673) 5-iodotubercidin 674) 5-KETOEICOSATETRAENOICACID 675) 5′-N-Ethylcarboxamidoadenosine (NECA) 676) 6,7-ADTN HBr 677)6-FORMYLINDOLO [3,2-B] CARBAZOLE 678) 7,7- DIMETHYLEICOSADIENOIC ACID679) 8,9-EPOXYEICOSATRIENOIC ACID 680) 8-methoxymethyl-IBMX 681)9(S)-HODE 682) 9(S)-HPODE 683) 9,10-OCTADECENOAMIDE 684) A-3 685) AA-861686) acetyl (N)-s-farnesyl-1-cysteine 687) ACETYL-FARNESYL- CYSTEINE688) Ac-Leu-Leu-Nle-CHO 689) ACONITINE 690) actinomycin D 691) ADRENICACID (22:4, n-6) 692) 1 mM 693) AG-1296 694) AG1478 695) AG213(Tyrphostin 47) 696) AG-370 697) AG-490 698) AG-879 699) AGC 700) AGGC701) Ala-Ala-Phe-CMK 702) alamethicin 703) Alrestatin 704) AM 92016 704)AM-251 706) AM-580 707) AMANTIDINE 708) AMILORIDE 709)Amino-1,8-naphthalimide [4- Amino-1,8-522) naphthalimide] 710)Aminobenzamide (3-ABA) [3- 522) aminobenzamide (3-ABA)] 711) AMIODARONE712) ANANDAMIDE (18:2, n-6) 713) ANANDAMIDE (20:3, n-6) 714) ANANDAMIDE(20:4, n-6) 715) ANANDAMIDE (22:4, n-6) 716) anisomycin 717) aphidicolin718) ARACHIDONAMIDE 719) ARACHIDONIC ACID (20:4, n- 6) 720)ARACHIDONOYL-PAF 721) aristolochic acid 722) Arvanil 723) ascomycin(FK-520) 724) B581 725) BADGE 726) bafilomycin A1 727) BAPTA-AM 728) BAY11-7082 729) BAY K-8644 730) BENZAMIL 731) BEPRIDIL 732) Bestatin 733)beta-lapachone 734) Betulinic acid 735) bezafibrate 736) Blebbistatin737) BML-190 738) Boc-GVV-CHO 739) bongkrekic acid 740) brefeldin A 741)Bromo-7-nitroindazole [3-Bromo- 7-nitroindazole] 742) Bromo-cAMP[8-Bromo-cAMP] 743) Bromo-cGMP [8-Bromo-cGMP] 744) bumetanide 745) BW-B70C 746) C16 CERAMIDE 747) C2 CERAMIDE 748) C2 DIHYDROCERAMIDE 749) C8CERAMIDE 750) C8 CERAMINE 750) C8 DIHYDROCERAMIDE 751) CA-074-Me 753)calpeptin 754) calphostin C 755) calyculin A 756) camptothecin 757)cantharidin 758) CAPE 759) capsacin(E) 760) capsazepine 761) CARBACYCLIN762) castanospermine 763) CDC 764) Cerulenin 765) CGP-37157 766)chelerythrine 767) CIGLITAZONE 768) CIMATEROL 769) CinnGEL 2Me 770)CIRAZOLINE 771) CITCO 772) CLOFIBRATE 773) clonidine 774) CLOPROSTENOLNa 775) clozapine 776) C-PAF 777) Curcumin 778) Cyclo[Arg-Gly-Asp-D-Phe-Val] 779) cycloheximide 780) protein synthesisinhibitor 781) cycloheximide-N-ethylethanoate 782) cyclopamine 783)CYCLOPIAZONIC ACID 784) cyclosporin A 785) cypermethrin 786)cytochalasin B 787) cytochalasin D 788) D12-PROSTAGLANDIN J2 789) D609790) damnacanthal 791) DANTROLENE 792) decoyinine 793) Decylubiquinone794) deoxymannojirimycin(1) 795) deoxynorjrimycin(1) 796) Deprenyl 797)DIAZOXIDE 798) dibutyrylcyclic AMP 799) dibutyrylcyclic GMP 800)DICHLOROBENZAMIL 801) DIHOMO-GAMMA- LINOLENIC ACID 802)DIHYDROSPHINGOSINE 803) DIINDOLYLMETHANE 804) DILTIAZEM 805)diphenyleneiodonium Cl 806) dipyridamole 807) DL-DIHYDROSPHINGOSINE 808)DL-PDMP 809) DL-PPMP 810) DOCOSAHEXAENOIC ACID (22:6 n-3) 811)DOCOSAPENTAENOIC ACID 812) DOCOSATRIENOIC ACID (22:3 n-3) 813)doxorubicin 814) DRB 815) E-4031 816) E6 berbamine 817) E-64-d 818)Ebselen 819) EHNA HCl 820) EICOSA-5,8-DIENOIC ACID (20:2 n-12) 821)EICOSADIENOIC ACID (20:2 n-6) 822) EICOSAPENTAENOIC ACID (20:5 n-3) 823)EICOSATRIENOIC ACID (20:3 n-3) 824) ENANTIO-PAF C16 825) epibatidine(+/−) 826) etoposide 827) FARNESYLTHIOACETIC ACID 828) FCCP 829)FIPRONIL 830) FK-506 831) FLECAINIDE 832) FLUFENAMIC ACID 833)FLUNARIZINE 834) FLUPROSTENOL 835) FLUSPIRILINE 836) FPL-64176 837)Fumonisin B1 838) Furoxan 839) GAMMA-LINOLENIC ACID (18:3 n-6) 840)geldanamycin 841) genistein 842) GF-109203X 843) GINGEROL 844) Gliotoxin845) GLIPIZIDE 846) GLYBURIDE 847) GM6001 848) Go6976 849) GRAYANOTOXINIII 850) GW-5074 851) GW-9662 852) H7] 853) H-89 854) H9 855) HA-1004856) HA1077 857) HA14-1 858) HBDDE 859) Helenalin 860) Hinokitiol 861)HISTAMINE 862) HNMPA-(AM)3 863) Hoechst 33342 (cell permeable)(BisBenzimide) 864) Huperzine A [(−)-Huperzine A] 865) IAA-94 866)IB-MECA 867) IBMX 868) ICRF-193 869) Ikarugamyin 870) Indirubin 871)Indirubin-3′-monoxime 872) indomethacin 873) juglone 874) K252A 875)Kavain (+/−) 876) KN-62 877) KT-5720 878) L-744,832 879) Latrunculin B880) Lavendustin A 881) L-cis-DILTIAZEM 882) LEUKOTOXIN A (9,10-EODE)883) LEUKOTOXIN B (12,13-EODE) 884) LEUKOTRIENE B4 885) LEUKOTRIENE C4886) LEUKOTRIENE D4 887) LEUKOTRIENE E4 888) Leupeptin 889) LFM-A13 890)LIDOCAINE 891) LINOLEAMIDE 892) LINOLEIC ACID 893) LINOLENIC ACID (18:3n-3) 894) LIPOXIN A4 895) L-NAME 896) L-NASPA 897) LOPERAMIDE 898)LY-171883 899) LY-294002 900) LY-83583 901) Lycorine 902) LYSO-PAF C16903) Manoalide 904) manumycin A 905) MAPP, D-erythro 906) MAPP,L-erythro 907) mastoparan 908) MBCQ 909) MCI-186 910) MDL-28170 911)MEAD ACID (20:3 n-9) 912) MEAD ETHANOLAMIDE 913) methotrexate 914)METHOXY VERAPAMIL 915) Mevinolin (lovastatin) 916) MG-132 917) Milrinone918) MINOXIDIL 919) MINOXIDIL SULFATE 920) MISOPROSTOL, FREE ACID 921)mitomycin C 922) ML7 923) ML9 924) MnTBAP 925) Monastrol 926) monensin927) MY-5445 928) Mycophenolic acid 929) N,N-DIMETHYLSPHINGOSINE 930)N9-Isopropylolomoucine 931) N-ACETYL-LEUKOTRIENE E4 932)NapSul-Ile-Trp-CHO 933) N-ARACHIDONOYLGLYCINE 934) NICARDIPINE 935)NIFEDIPINE 936) NIFLUMIC ACID 937) Nigericin 938) NIGULDIPINE 939)Nimesulide 940) NIMODIPINE 941) NITRENDIPINE 942) N-LINOLEOYLGLYCINE943) nocodazole 944) N-PHENYLANTHRANILIC (CL) 945) NPPB 946) NS-1619947) NS-398 948) NSC-95397 949) OBAA 950) okadaic acid 951) oligomycin A952) olomoucine 953) ouabain 954) PAF C16 955) PAF C18 956) PAF C18:1957) PALMITYLETHANOLAMIDE 958) Parthenolide 959) PAXILLINE 960) PCA 4248961) PCO-400 962) PD 98059 963) PENITREM A 964) pepstatin 965) PHENAMIL966) Phenanthridinone [6(5H)- Phenanthridinone] 967) Phenoxybenzamine968) PHENTOLAMINE 969) PHENYTOIN 970) PHOSPHATIDIC ACID, DIPALMITOYL971) Piceatannol 972) pifithrin 973) PIMOZIDE 974) PINACIDIL 975)piroxicam 976) PP1 977) PP2 978) prazocin 979) Pregnenolone 16alphacarbonitrile 980) PRIMA-1 981) PROCAINAMIDE 982) PROPAFENONE 983)propidium iodide 984) propranolol (S−) 985) puromycin 986) quercetin987) QUINIDINE 988) QUININE 989) QX-314 990) rapamycin 991) resveratrol992) RETINOIC ACID, ALL TRANS 993) REV-5901 994) RG-14620 995) RHC-80267996) RK-682 997) Ro 20-1724 998) Ro 31-8220 999) Rolipram 1000)roscovitine 1001) Rottlerin 1002) RWJ-60475-(AM)3 1003) RYANODINE 1004)SB 202190 1005) SB 203580 1006) SB-415286 1007) SB-431542 1008)SDZ-201106 1009) S-FARNESYL-L-CYSTEINEME 1010) Shikonin 1011) siguazodan1012) SKF-96365 1013) SP-600125 1014) SPHINGOSINE 1015) Splitomycin1016) SQ22536 1017) SQ-29548 1018) staurosporine 1019) SU-4312 1020)Suramin 1021) swainsonine 1022) tamoxifen 1023) Tanshinone IIA 1024)taxol = paclitaxel 1025) TETRAHYDROCANNABINOL-7- OIC ACID 1026)TETRANDRINE 1027) thalidomide 1028) THAPSIGARGIN 1029) Thiocitrulline[L-Thiocitrulline HCl] 1030) Thiorphan 1031) TMB-8 1032) TOLAZAMIDE1033) TOLBUTAMIDE 1034) Tosyl-Phe-CMK (TPCK) 1035) TPEN 1036) Trequinsin1037) trichostatin-A 1038) trifluoperazine 1039) TRIM 1040) Triptolide1041) TTNPB 1042) Tunicamycin 1043) tyrphostin 1 1044) tyrphostin 91045) tyrphostin AG-126 1046) tyrphostin AG-370 1047) tyrphostin AG-8251048) Tyrphostin-8 1049) U-0126 1050) U-37883A 1051) U-46619 1052)U-50488 1053) U73122 1054) U-74389G 1055) U-75302 1056) valinomycin1057) Valproic acid 1058) VERAPAMIL 1059) VERATRIDINE 1060) vinblastine1061) vinpocetine 1062) W7 1063) WIN 55,212-2 1064) Wiskostatin 1065)Wortmannin 1066) WY-14643 1067) Xestospongin C 1068) Y-27632 1069) YC-11070) Yohimbine 1071) Zaprinast 1072) Zardaverine 1073) ZL3VS 1074)ZM226600 1075) ZM336372 1076) Z-prolyl-prolinal 1077) zVAD-FMK 1078)Ascorbate 1079) 5-azacytidine 1080) 5-azadeoxycytidine 1081)Hexamethylene bisacetamide (HMBA) 1082) Sodium butyrate 1083) Dimethylsulfoxide. 1084) Goosecoid 1085) Glycogen synthase kinase-3 1086)Galectin-1 1087) Galectin-3 Cell Adhesion Molecules 1086) Cadherin 1(E-Cadherin) 1087) Cadherin 2 (N-Cadherin) 1088) Cadherin 3 (P-Cadherin)1089) Cadherin 4 (R-Cadherin) 1090) Cadherin 5 (VE-Cadherin) 1091)Cadherin 6 (K-Cadherin) 1092) Cadherin 7 1093) Cadherin 8 1094) Cadherin9 1095) Cadherin 10 1096) Cadherin 11 (OB-Cadherin) 1097) Cadherin 12(BR-Cadherin) 1098) Cadherin 13 (H-Cadherin) 1099) Cadherin 14 (same asCadherin 18) 1100) Cadherin 15 (M-Cadherin) 1101) Cadherin 16(KSP-Cadherin) 1102) LI CadherinThe foregoing is exemplary of the factors and conditions that can beused to promote differentiation of ES cells or ED cells along particulardevelopmental lineages. Partially or terminally differentiatedendodermal, mesodermal, or ectodermal cell types can be used inscreening assays, to study developmental and stem cell biology, or toproduce therapeutics. Partially or terminally differentiated cell typescan optionally be substantially purified, formulated as pharmaceuticalpreparations, and/or cryopreserved.Pluripotency of ES Cells

Pluripotency of the human ES cells or cell lines produced by the methodsof this invention can be determined by detecting expression of human EScell marker proteins. Examples of such proteins include but are notlimited to octamer binding protein 4 (Oct-4), stage-specific embryonicantigen (SSEA)-3, SSEA-4, TRA-1-60, TRA-1-81 and alkaline phosphatase.In some embodiments, the putative ES cell lines maintain pluripotencyafter more than 13, 20, 30, 40, 50, 60, 70, 80, 90 or 100 passages. TheES cells may also be assayed for maintenance of normal karyotype.Pluripotency may also be confirmed by differentiating the ES cellproduced by the methods of this invention into cells of ectoderm,endoderm and mesoderm lineage using methods known in the art.Pluripotency may also be tested by transplanting ES cells in vivo, forexample into an immunodeficient mouse (such as a SCID mouse), andevaluating teratoma formation.

In certain embodiments, the ES cells or cell lines produced from ablastomere express one or more ES cell marker protein. Additionally oralternatively, in certain embodiments, the cells maintain a normalkaryotype. Additionally or alternatively, in certain embodiments, thecells maintain pluripotency after more than 13, 20, 30, 40, 50, 60, 70,80, 90 or 100 passages.

For any of the foregoing, the ES cell or cell line produced from ablastomere can be generated without destroying the embryo from which theblastomere used to generate the cell or line is obtained. Thischaracteristic of the cells distinguishes these cells from currentlyavailable ES cells and lines which were generated using methods thatnecessarily destroyed the underlying embryo.

Production of TS Cells

This invention also provides methods of directly differentiating celltypes from isolated blastomeres before and without generating ES celllines. In one example, human trophoblast stem (“TS”) cells are producedby contacting blastomere outgrowths, which morphologically resembletrophoblast and/or extraembryonic endoderm, but which do not resemble EScells, with FGF-4. For example, FGF-4 is added to the culture media ofthe outgrowths. TS cells can be detected by assaying expression ofproteins such as cdx-2, fgfr2, PL-1 and human chorionic gonadotropin(hCG) using procedures standard in the art. TS cell identification canalso be evidenced by absence of the expression of proteins such as, butnot limited to, Oct-4 and α-feto protein.

Production of Purified Preparations and Cell Lines

In certain embodiments, cell lines can be produced. By way of example,once a particular cell type is identified in a culture comprising acluster of two or more blastomeres (blastomere-derived outgrowths), thatcell can be separated from the remainder of the culture for further use.Once separated, the desired cell can be propagated as a purified orsubstantially purified population, or it can be maintained as a cellline.

In certain embodiments, an ES cell produced from culturing a blastomereobtained from an embryo is separated from the culture ofblastomere-derived outgrowths, and an ES cell line is established usingstandard techniques developed when establishing ES cell lines fromblastocyst stage embryos. In other embodiments, a partiallydifferentiated ED cell of interest can be select based on, for example,morphology and that cell can be separated from the culture and purifiedor otherwise further analyzed.

Exemplary cell lines include stable cell lines. ES cell linesestablished in this way may have the properties of existing ES celllines, for example, differentiation potential, protein expression,karyotype, and the like. Alternatively, ES cell lines established inthis way may differ from existing ES cell lines in one or more ways.

Therapeutic Uses of ES and ED Cells

The ES or ED cells of this invention are suitable for any use for whichES cells are useful. The present invention provides a method of treatinga disorder amenable to cell therapy comprising administering to theaffected subject a therapeutically effective amount of the ES cells ofthe invention.

In one embodiment the methods of the invention are used to remove ablastomere preceding implantation of a human embryo after which theblastomere would be cultured as described above in order to derive andstore human ES cells for therapeutic uses using cell therapy should thechild resulting from the human embryo require, for example, diseasetherapy, tissue repair, transplantation, treatment of a cellulardebilitation, or treatment of cellular dysfunctions in the future.

In another embodiment of the invention, cells derived from a blastomere,precompaction morula, compacting morula, or sectioned blastocyst aredirectly differentiated in vitro or in vivo to generate differentiatingor differentiated cells without generating an embryonic stem cell line.See U.S. patent publication no. 20050265976, published Dec. 1, 2005, andinternational patent publication no. WO0129206, published Apr. 26, 2001,the disclosures of which are hereby incorporated by reference herein formethods of direct differentiation. The cells of the invention are usefulin medical, veterinary and biological research and in the treatment ofdisease by providing cells for use in cell therapy, e.g., allogeneiccell therapy.

In another embodiment, an ES cell or cell line is derived from ablastomere and the ES cell or cell line is induced to differentiate toproduce one or more mesodermal, endodermal, or ectodermal cell types.Exemplary cell types include, but are not limited to, RPE cells,hematopoietic stem cells, hematopoietic cell types (e.g., RBCs,platelets, etc.), pancreatic beta cells, skin cells, cardiomyocytes,smooth muscle cells, endothelial cells, hepatocytes, neurons, glia,skeletal muscle cells, vascular cells, and the like. Although ES cellsmay themselves be used in the treatment of diseases or disorders, theinvention also contemplates the productions of differentiated cell typesthat can be used therapeutically.

The methods of the present invention may be used to generate stem cellsfrom blastomeres wherein the stem cells are hemizygous or homozygous forMHC antigens. These cells are useful for reduced immunogenicity duringtransplantation and cell therapy. The stem cells so produced may beassembled into a bank with reduced complexity in the MHC genes. Theblastomeres of this invention could be derived from embryos that arehemizygous or homozygous for MHC antigens. These embryos may be eitherselected to be hemizygous or homozygous for MHC antigens or made, by anymethods known in the art, to be hemizygous or homozygous for MHCantigens. Alternatively stem cells derived from blastomeres may be madehemizygous or homozygous for MHC antigens, e.g., by gene targeting. See,e.g., WO 03/018760 published Mar. 6, 2003 and U.S. provisional patentapplication No. 60/729, 173 the disclosures of which are incorporatedherein in their entirety.

The ES cells and human embryo-derived cells generated by theabove-mentioned novel techniques are utilized in research relating tocell biology, drug discovery, and in cell therapy, including but notlimited to, production of hematopoietic and hemangioblastic cells forthe treatment of blood disorders, vascular disorders, heart disease,cancer, and wound healing, pancreatic beta cells useful in the treatmentof diabetes, retinal cells such as neural cells and retinal pigmentepithelial cells useful in the treatment of retinal disease such asretinitis pigmentosa and macular degeneration, neurons useful intreating Parkinson's disease, Alzheimer's disease, chronic pain, stroke,psychiatric disorders, and spinal cord injury, heart muscle cells usefulin treating heart disease such as heart failure, skin cells useful intreating wounds for scarless wound repair, burns, promoting woundrepair, and in treating skin aging, liver cells for the treatment ofliver disease such as cirrhotic liver disease, kidney cells for thetreatment of kidney disease such as renal failure, cartilage for thetreatment of arthritis, lung cells for the treatment of lung disease andbone cells useful in the treatment of bone disorders such asosteoporosis.

Such cell therapy methods may involve use of the ES cells of thisinvention in combination with proliferation factors, lineage-commitmentfactors, or gene or proteins of interest. Treatment methods may includeproviding stem or appropriate precursor cells directly fortransplantation where the tissue is regenerated in vivo or recreatingthe desired tissue in vitro and then providing the tissue to theaffected subject.

Pharmaceutical Preparations

The invention provides methods of generating ES cells, ES cell lines, TScells, and various partially and terminally differentiated cells andcell lines. Cells and cell lines so produced can be studied in vitro andin vivo. In certain embodiments, the study of these cells providesinformation about basic developmental biology and stem cell biology. Incertain other embodiments, the study of these cells and/or the factorsthat can be used to manipulate the proliferation, differentiation, andsurvival of these cells can be used to develop stem-cell based therapiesto treat or ameliorate any of a variety of diseases or conditions. Inother embodiments, cells and cell lines produced by these methods can beused in screening assays to identify agents and conditions that can beused therapeutically. Identified therapeutics may be used to developcellular therapies or may themselves be useful when delivered topatients.

In certain embodiments, ES cells, ES cell lines, TS cells, TS celllines, or partially or terminally differentiated cells may be formulatedas pharmaceutical preparations by combining the cells with apharmaceutically acceptable carrier or excipient. In certainembodiments, the pharmaceutical preparation contains a certain number ofcells per unit volume of carrier so that cellular therapies can beadministered to deliver a particular dosage of cells. For example,pharmaceutical preparations can be formulated to permit delivery of, forexample, 1×10⁵, 1×10⁶, 2×10⁶, 3×10⁶, 4×10⁶, 5×10⁶, 1×10⁷, or greaterthan 1×10⁷ cells in a volume of carrier appropriate for the conditionbeing treated and the route of administration.

Methods of Conducting Research

As detailed above, embryonic stem cell research has been partiallyhindered by political and ethical opposition to the destruction ofembryos. The present invention not only provides an alternative methodfor efficiently generating cells and cell lines, including ES cells andcell lines, the present invention also provides a method that does notrequire that new embryos be destroyed as part of the process of ES cellderivation. Remaining embryos can be cryopreserved and perpetuallypreserved or reserved for additional, future research use.

For some, the ability to derive ES cells and cell lines (or partially orterminally differentiated cell types differentiated from ES cells ordirectly differentiated from embryos) without necessarily destroying newembryos will provide substantial benefits beyond the significanttechnical advanced reflected in these methods. As such, the inventionprovides novel methods of conducting embryonic stem cell researchwithout destroying a human embryo. The method entails obtaining a humanES cell or ES cell line derived from a human embryo but withoutdestroying that human embryo. The ES cell or cell line can be generatedfrom a blastomere obtained from a human embryo using any of themethodologies disclosed herein. Once an ES cell or cell line is derived,the method further entails conducting embryonic stem cell research usingthe human ES cell or ES cell line. The method provides an avenue forconducting ES cell research without the need to destroy new embryos.

In certain embodiments, the embryonic stem cell research involvesresearch examining the differentiation potential of ES cells or celllines. For example, the research may involve contacting the human EScell or ES cell line with one or more factors, and identifying factorsthat promote differentiation of the ES cell or ES cell line to one ormore mesodermal, endodermal, or ectodermal cell types. In otherembodiments, the embryonic stem cell research involves the study ofpossible therapeutic uses of ES cells or cell differentiated there from.

Regardless of the particular research use, this method may expand theopportunities for collaboration with researchers around the world,particularly researchers working in countries with laws regulatingembryo destruction.

Unless otherwise defined, all technical and scientific terms used hereinhave the same meaning as commonly understood by one of ordinary skill inthe art. In case of conflict, the present specification, includingdefinitions, will control. Further, unless otherwise required bycontext, singular terms shall include pluralities and plural terms shallinclude the singular. Generally, nomenclatures used in connection with,and techniques of, cell and tissue culture, molecular biology,immunology, microbiology, genetics, developmental biology, cell biologydescribed herein are those well-known and commonly used in the art.Exemplary methods and materials are described below, although methodsand materials similar or equivalent to those described herein can alsobe used in the practice or testing of the present invention.

All publications and other references mentioned herein are incorporatedby reference in their entirety. Although a number of documents are citedherein, this citation does not constitute an admission that any of thesedocuments forms part of the common general knowledge in the art.

Throughout this specification and claims, the word “comprise,” orvariations such as “comprises” or “comprising” will be understood toimply the inclusion of a stated integer or group of integers but not theexclusion of any other integer or group of integers.

In order for that this invention may be better understood, the followingexamples are set forth. These examples are for purposes of illustrationonly and are not be construed as limiting the scope of the invention inany matter.

EXAMPLE 1 Generation of Human ES Cell Lines

Unused embryos produced by in-vitro fertilization for clinical purposeswere obtained. Six of these embryos were Grade I or II (symmetrical andeven cell division with little or no cytoplasmic fragmentation), whereasthe remaining ten embryos were Grade III (variable fragmentation) usingstandard scoring system (Veeck, L. L. et al., An Atlas of Human Gametesand Conceptuses, Parthenon, New York, N.Y., 1999). Embryos withblastomeres of unequal size and moderate-to-severe fragmentation (GradesIV and V) were excluded from this study. Pronuclear and multi-cell stagehuman embryos were thawed and cultured until the 8-10 cell stage at 37 Cin 20 μl drops of Quinn's cleavage medium (Cooper Surgical Inc., Cat #ART1526) under paraffin oil (Cooper Surgical Inc. Cat # 4008) in a highhumidified incubator with 5.5% CO₂/5% O₂/89.5% N₂.

The zona pellucida was disrupted using either Acidic Tyroides solutionor multiple Piezo-pulses and individual blastomeres were mechanicallyseparated from the denuded embryos by holding the embryo with amicropipette and gently tapping the pipette holder. The separatedblastomeres were cultured together in the same media (Quinn's cleavagemedium (Cooper Surgical Inc., Cat # ART1526)) and arranged so as toavoid contact with each other by using depressions created in the bottomof the plastic tissue culture plate as previously described (Nagy, A. etal., Manipulating the Mouse Embryos: A Laboratory Manual, Cold SpringHarbor Laboratory Press, Cold Spring Harbor, N.Y. 2002).

The majority (58%) of the isolated blastomeres divided at least once andapproximately half of these (28 out of 53) formed vesicles or clumpswhich produced cellular outgrowths within 2-3 days (FIG. 1B,C). Duringthis process, sets of microdrops were prepared consisting of a 50 μldrop of blastomere medium (Quinn's blastocyst medium, Coopers SurgicalInc. Cat # ART1529) containing a blastomere-derived aggregate surroundedby several microdrops of hES culture medium (Knockout-DMEM (InvitrogenCat # 10829-018 supplemented with 5% plasmanate, 5% serum replacement,10% fetal bovine serum, 20 ng/ml leukemia inhibiting factor (LIF) and8-16 ng/ml basic fibroblast growth factor (bFGF)) containing greenfluorescent protein (GFP)-labeled hES cells growing on a mitomycinC-treated mouse embryonic fibroblasts (MEF) feeder layer. Previousexperiments in mice (Chung et al., Nature (2006) 439:216-219) indicatedthat cell co-culture is important for ES cell derivation from singleblastomeres. However, the aggregation system used in these previousstudies could not be employed because, unlike in the mouse, humanblastomeres do not form tight aggregates with ES cells. Thus, themicrodrops containing the blastomere-derived vesicles/clumps were mergedwith one or two surrounding microdrops seeded with mitomycin-C treatedmouse embryonic fibroblasts (MEFs) and GFP-positive human embryonic stem(hES) cells by scraping the bottom of the plate between the drops with aglass capillary.

After formation of initial outgrowths approximately half of the mediumwas changed every other day until the outgrowths reached approximately50-100 cells. Although the initial outgrowths generally contained cellsof different morphologies over a period of several days we observedseveral fates: (1) cells resembling trophectoderm took over, (2) cellsthat initially resembled ES-cells differentiated, or (3) ES-like cellscontinued undifferentiated proliferation. All of these outcomes aretypical of derivation of ES cells from human embryos, especially whenintact blastocysts are plated without removal of the trophectoderm usingimmunosurgery. The putative human ES cells were mechanically passagedonto fresh MEF feeder layers in hES culture medium which was changedevery 1-2 days. The colonies were passaged by mechanical dispersion andtransferred to fresh feeders every 2-3 days until enough cells wereproduced to initiate adaption to trypsin. The colony morphology, growthrate, procedures and culture media used were very similar to those ofblastocyst-derived ES cells.

Karyotyping of the cells derived from the human blastomere weredetermined using the following procedure: Cells were passaged ontogelatin in ES culture medium which was replaced the day before harvestuntil the cells were approximately 50% confluent. Colcemid (Invitrogen)was added to the culture at a concentration of 0.12 μg/ml for 40minutes. The cells were then rinsed twice with PBS and then trypsinizedand centrifuged in DMEM (Invitrogen) with 10% FBS (Hyclone). 0.075 M KClwas added to the pellet and the cells were incubated for 10 minutes at37° C. The cells were then centrifuged and fixed with 3:1methanol/acetic acid (Baker) for 10 minutes, centrifuged again andsuspended in this fixative. Cytogenetic analysis was performed onmetaphase cells using G-banding on 10 cells.

Results of these experiments are shown in Table 1. The results in row 10of Table 1 were obtained using the method of isolating ES cells asdescribed in Chung et al., Nature (2006) 439:216-219. Nineteen ES celllike outgrowths and two stable human ES cell lines (MA01 and MA09) wereobtained. The MA01 and MA09 cell lines maintained undifferentiatedproliferation for more than seven months. Although the initialoutgrowths generally contained cells of different morphologies, over aperiod of several days, fates typical of derivation of ES cells fromhuman blastocysts were observed. For example, two of the six grade I/IIembryos used generated stable hES cell lines that exhibited normalkaryotpe (line MA01 46, XX; line MA09 46, XX; FIG. 3(h)) and maintainedmolecular markers of pluripotency up to more than 25 passages (FIG. 3(a)to (g)). Both lines are also positive for alkaline phosphatase andexpress Oct-4, SSEA-3, SSEA-4, TRA-1-60 and TRA-1-81 (FIG. 7).Microsatellite analysis ruled out contamination of the lines with the EScells used for co-culture with other hES cell lines in the laboratory.Karyotype and microsatellite analysis ruled out fusion (both new lineswere female and the WA01 human ES cells used for co-culture were male)(FIG. 5(d)).

Polymerase chain reaction (PCR) analysis further confirmed the absenceof GFP and Y-chromosome gene sequences in both blastomere-derived humanES cell lines (FIG. 5(a) to (c)). Conventional PCR reactions wereperformed with 100 ng genomic DNA, Amplitaq Gold polymerase (ABI, FosterCity, Calif.), and primer pairs specific for FES/FPS, vWA31, D22S417,D10S526 and D5S592 genomic microsatellite sequences (Coriell, Camden,N.J.). Single primers in each pair were end-labeled with a 6-Famfluorescent label. After incubation for 10 min at 94° C. to activate thepolymerase, amplification was performed with 30 cycles of 94° C. for 45sec, 56° C. for 60 sec, and 72° C. for 60 sec. Labeled amplicons wereseparated and sized using an ABI 3730 sequencer. For amplification ofeGFP, amelogenin and SRY genes, genomic DNA was isolated using a QIAampDNA Mini Kit (Qiagen), and 200 ng DNA per reaction in 50 μl was used foreGFP, amelogenin and SRY amplification. Primers used for eGFP wereforward 5′-TTGAATTCGCCACCATGGTGAGC-3′ (SEQ ID NO: 1) and reverse5′-TTGAATTCTTACTTGTACAGCTCGTCC-3′ (SEQ ID NO: 2) and PCR reactions wereperformed as described previously. For sex determination, bothamelogenin and SRY genes were amplified by PCR. Primers used foramelogenin gene were forward 5′-CTCATCCTGGGCACCCTGGTTATATC-3′ (SEQ IDNO: 3), reverse, 5′-GGTACCACTTCAAAGGGGTAAGCAC-3′ (SEQ ID NO: 4), whichgenerated a fragment of 1310 bp for Y-chromosome and a fragment of 1490bp for X-chromosome. For Y-chromosome specific SRY gene, primers usedwere forward 5′-GATCAGCAAGCAGCTGGGATACCAGTG-3′ (SEQ ID NO: 5), andreverse 5′-CTGTAGCGGTCCCGTTGCTGCGGTG-3′ (SEQ ID NO: 6), which amplifieda DNA fragment of 330 bp. As a control for PCR reactions, myogeninprimers, forward 5′-TCACGGTGGAGGATATGTCT-3′ (SEQ ID NO: 7) and reverse5′-GAGTCAGCTAAATTCCCTCG-3′ (SEQ ID NO: 8) were included in SRY PCRreactions, which generated a fragment of 245 bp. PCR products wereseparated on an agarose gel and visualized by ethidium bromide staining.

Although only two of the six (33%) grade I/II embryos (or 2 out of the35 blastomeres; 2 out of 91 blastomeres including grade III-V embryos)generated hES cell lines, this success rate is similar to that producedusing conventional methods. We believe the success rate can be furtherincreased by optimizing conditions at the earliest stages of blastomereoutgrowth. TABLE 1 Embryonic stem-cells derived from single humanblastomeres No. No. No. No. ES cell- No. ES cell Exp. embryosblastomeres blastomeres No. like lines No. used retrieved that dividedoutgrowths outgrowths established Comments 1 2 10 4 1 0 0 w/o ESco-culture 2 1 6 3 0 0 0 w/o ES co-culture 3 2 11 6 5 4 1 ES co-culture4 1 7 6 1 1 0 ES co-culture 5 2 12 7 3 3 0 ES co-culture 6 2 12 7 5 4 1ES co-culture 7 2 11 7 4 3 0 ES co-culture 8 1 6 3 0 0 0 ES co-culture 91 4 3 3 2 0 ES co-culture 10 2 12 7 6 2 0 ES aggregation (differenttechnique) Total 16 91 53 28 19 2

EXAMPLE 2 Differentiation of Human ES Cells

The ability of the human ES cells to differentiate into different germlayers was analyzed both in vitro and in teratomas using techniquesknown in the art.

Briefly, for the in vitro experiments, the human ES cells were separatedby treating with either collagenase or trypsin and then cultured in cellculture dishes without feeder cells in embryoid body (EB) medium.Approximately one week later, the ES cells formed embryoid bodies (EB).The EBs were then fixed in 4% formaldehyde, washed in PBS, embedded inparaffin, sectioned and analyzed for the presence of derivatives fromendoderm, mesoderm and ectoderm using tissue specific antibodies (α-fetoprotein for primitive endoderm, muscle actin for mesoderm, and β IIItubulin for ectoderm) (FIG. 4).

The single blastomere-derived human ES cell could also be differentiatedin vitro into cells of specific therapeutic interest, includingendothelial cells which after replating on Matrigel, formed typicalcapillary-vascular like structures (FIG. 4(e)) that expressed highlevels of von Willebrand Factor (vWF) and took up acetylatedlow-density-lipoprotein (Ac-LDL) (FIG. 4(f)). Retinal pigment epithelium(RPE) clusters also appeared in adherent human ES cell cultures and inembryoid bodies and were used to establish passageable RPE lines usingmethods known in the art. These RPE lines displayed pigmented phenotypeand typical “cobblestone” morphology (FIG. 4(g)), bestrophinimmunostaining (FIG. 4(h)) and expressed bestrophin, RPE65, CRALBP andPEDF as shown by RT-PCR (FIG. 4(i) and FIG. 8).

To induce teratomas, small clumps of 50-100 hES cells were mechanicallyremoved from the culture and transplanted under the kidney capsules of6-8 week old NOD-SCID mice under anesthesia. After 2-3 weeks, thekidneys were removed, fixed with 4% paraformaldehyde overnight, washedfor 24 hours in PBS, embedded in paraffin, sectioned and analyzed forthe presence of the derivatives of three germ layers: endoderm, mesodermand ectoderm. Alternatively, approximately 1 million hES cells wereinjected into the rear thigh of NOD-SCID mice. After approximately twomonths the mice were sacrificed and the teratomas excised, fixed in 4%paraformaldehyde, embedded in paraffin and sectioned.

The presence of different germ layers was assayed by determining thepresence of molecular markers: β III tubulin for ectoderm, smooth muscleactin for mesoderm, and α-feto protein for endoderm (FIGS. 1F-H). Theteratomas contained tissues from all three germ layers including neuralrosettes (ectoderm), liver and hematopoietic cells (mesoderm) and liver,respiratory and intestinal epithelia (endoderm) among others (FIG.4(a)). For immunohistochemical analysis, cells were fixed with 2%paraformaldehye, permeabilized with 0.1% NP-40 and blocked with 10% goatserum, 10% donkey serum (Jackson Immunoresearch Laboratories, WestGrove, Pa.) in PBS (Invitrogen) for one hour. Incubation with primaryantibodies was carried out overnight at 4 C. After washing in PBScontaining 0.1% Tween-20, fluorescently labeled or biotinylatedsecondary antibodies (Jackson Immunoresearch Laboratories, West Grove,Pa.) were added for one hour; some samples were subsequently incubatedfor 15 minutes with fluorescently labeled Steptavidin (Amersham,Piscataway, N.J.). After additional washing in PBS/Tween, specimens weremounted using Vectashield with DAPI (Vector Laboratories, Burlingame,Calif.) and observed using a fluorescent microscope (Nikon). Alkalinephosphatase was detected using the Vector Red kit (vector Laboratories,Burlingame, Calif.) according to the manufacturer's instructions.Antibodies used were anti-Oct-4 (Santa Cruz Biotechnology, Santa Cruz,Calif.), anti-SSEA-3, anti-SSEA-4 (Developmental Studies Hybridoma Bank,University of Iowa), anti-TRA-1-60, anti-TRA-1-81 (Chemicon), tubulin βIII (BABCO, Berkeley, Calif.), anti-α-feto protein (DACO), andanti-smooth muscle actin (Sigma-Aldrich).

The blastomere-derived cell lines MA01 and MA09 appear to differentiatemore readily into certain cell types, For example, neural progenitorswere generated without the need for embryoid intermediates, stromalfeeder layers or low-density passaging. When transferred tolaminin-coated substrate and maintained in defined medium containinglaminin and basic fibroblast growth factor, they began to expressneuronal and neuronal progenitor markers such as Nestin, β III tubulinand Pax6. MA01 human ES cells also formed hematopoietic colony formingunits (CFU) 3-5 times more efficiently than WA01 (H1)-GFP cells and 5-10times more efficiently than WA09 (H9) cells. MA09 human ES cells showedsimilar potential as WA 09 cells for hemaopoietic differentiation butdemonstrated higher capability to differentiate toward endotheliallineage as compared to both WA01-GFP and WA09 cells.

EXAMPLE 3 Production of ED Cells

As can be seen in Table 1 above, the production of embryo-derived cellsfrom isolated blastomeres occurs more often than the production of EScell lines. Of 53 isolated blastomeres that divided, 19 cultures yieldeddirectly-differentiated cell types and only 2 yielded ES cell lines.FIG. 6 shows the variety of differentiated cell morphologies observed bydirect differentiation.

EXAMPLE 4 Production of ED-Derived Endoderm and Pancreatic Beta Cells

Isolated blastomeres as described herein or similar ED cells are addedonto mitotically-inactivated feeder cells that express high levels ofNODAL or cell lines that express members of the TGF beta family thatactivate the same receptor as NODAL such as CM02 cells that expressrelatively high levels of Activin-A, but low levels of Inhibins orfollistatin. The cells are then incubated for a period of five days inDMEM medium with 0.5% human serum. After five days, the resulting cellswhich include definitive endodermal cells are purified by flow cytometryor other affinity-based cell separation techniques such as magnetic beadsorting using an antibody specific to the CXCR4 receptor and thenpermeabilized and exposed to cellular extracts from isolated bovinepancreatic beta cells as described in U.S. application Ser. No.11/025,893 (published as US 20050265976), which is incorporated byreference. The resulting cells that have been induced toward beta celldifferentiation are then cloned using techniques described ininternational patent application no. PCT/US2006/013573 filed Apr. 11,2006 and U.S. Application No. 60/835,779, filed Aug. 3, 2006, thedisclosure of which are incorporated by reference. These cells are thendirectly differentiated into pancreatic beta cells or beta cellprecursors using techniques known in the art for differentiating saidcells from human embryonic stem cell lines or by culturing the cells oninducer cell mesodermal cell lines (see international patent applicationno. PCT/US2006/013573 filed Apr. 11, 2006 and U.S. Application No.60/835,779, filed Aug. 3, 2006, the disclosure of which are incorporatedby reference).

EXAMPLE 5 Derivation of Embryonic Stem Cells without Destruction of theEmbryo

Embryos produced by in-vitro fertilization for clinical purposes areobtained. Pronuclear and multi-cell stage human embryos are thawed andcultured until the 8-10 cell stage at 37° C. in 20 μl drops of Quinn'scleavage medium (Cooper Surgical Inc., Cat # ART1526) under paraffin oil(Cooper Surgical Inc. Cat # 4008) in a high humidified incubator with5.5% CO₂/5% O₂/89.5% N₂.

The zona pellucida is disrupted using either Acidic Tyroides solution ormultiple Piezo-pulses and an individual blastomere is mechanicallyseparated from each denuded embryo by holding the embryo with amicropipette and gently tapping the pipette holder. The embryos aresubsequently cryopreserved.

The separated blastomeres are cultured as in Example 1.

EXAMPLE 6 Isolation of a Single Blastomere for Derivation of EmbryonicStem Cells and Pre-Implantation Genetic Diagnosis

Embryos produced by in-vitro fertilization for clinical purposes areobtained. Pronuclear and multi-cell stage human embryos are thawed andcultured until the 8-10 cell stage at 37° C. in 20 μl drops of Quinn'scleavage medium (Cooper Surgical Inc., Cat # ART1526) under paraffin oil(Cooper Surgical Inc. Cat # 4008) in a high humidified incubator with5.5% CO₂/5% O₂/89.5% N₂.

The zona pellucida is disrupted using either Acidic Tyroides solution ormultiple Piezo-pulses and an individual blastomere is mechanicallyseparated from the denuded embryo by holding the embryo with amicropipette and gently tapping the pipette holder. The embryo issubsequently cryopreserved.

The separated blastomere undergoes cell division. One progeny cell isused for genetic testing and a different progeny cell is cultured as inExample 1 to produce a human ES cell.

1. A method of producing human embryonic stem (ES) cells, comprising:(a) culturing a blastomere obtained from a human embryo in mediumcontaining less than 5 mM glucose to generate a cluster of two or moreblastomeres; (b) directly or indirectly contacting the cultured clusterof two or more blastomeres with embryonic or fetal cells; and (c)culturing the cluster of two or more blastomeres of (b) to produce EScells.
 2. The method of claim 1, wherein (a) comprises culturing ablastomere obtained from a human embryo in medium containing less than 5mM glucose and having an osmolarity of less than 310 mosm to generate acluster of two or more blastomeres. 3-4. (canceled)
 5. The method ofclaim 1, wherein (a) comprises culturing two or more blastomeresobtained from a human embryo. 6-7. (canceled)
 8. The method of claim 1,wherein obtaining the blastomere from a human embryo yields a blastomereand a remaining human embryo, and the remaining human embryo is notdestroyed following obtaining the blastomere.
 9. (canceled)
 10. Themethod of claim 8, wherein the remaining human embryo is cryopreserved.11. The method of claim 1, wherein the blastomere is obtained from ahuman embryo after compaction of the morula.
 12. The method of claim 1,wherein the blastomere is obtained from a human embryo before formationof the blastocoel. 13-19. (canceled)
 20. The method of claim 1, whereinthe blastomere is obtained by immobilizing the embryo and tapping theimmobilized embryo until the blastomere is isolated. 21-29. (canceled)30. The method of claim 8, further comprising the step of isolating theES cells derived from the blastomere and culturing the ES cells togenerate an ES cell line.
 31. A human ES cell derived from a humanembryo but without destroying the human embryo, produced by the methodof claim
 8. 32. A human ES cell line derived from a human embryo butwithout destroying the human embryo, produced by the method of claim 30.33-34. (canceled)
 35. A differentiated cell or tissue derived from thehuman ES cell of claim 31, wherein the differentiated cell or tissue isa mesodermal, endodermal or ectodermal cell or tissue.
 36. A method ofproducing a desired differentiated cell or tissue, comprising inducingdifferentiation of the human ES cell of claim 31 into the desired cellor tissue.
 37. A differentiated cell or tissue produced by the method ofclaim
 36. 38. A method of treating a disorder amenable to cell therapyin a patient, comprising administering to the patient the human ES cellof claim
 31. 39. A method of treating a disorder amenable to celltherapy in a patient, comprising administering to the patient thedifferentiated cell or tissue of claim
 37. 40. A pharmaceuticalcomposition comprising the human ES cell of claim 31 and apharmaceutically acceptable carrier.
 41. A pharmaceutical compositioncomprising the human ES cell line of claim 32 and a pharmaceuticallyacceptable carrier.
 42. A method of producing a trophoblast stem (TS)cell, comprising: (a) culturing a blastomere obtained from a humanembryo in medium containing less than 5 mM glucose to generate a clusterof two or more blastomeres; (b) directly or indirectly contacting thecultured cluster of two or more blastomeres to embryonic or fetal cells;and (c) culturing the cluster of two or more blastomeres of (b) until TScells are produced. 43-48. (canceled)
 49. The method of claim 42,wherein obtaining the blastomere from a human embryo yields a blastomereand a remaining human embryo, and the remaining human embryo is notdestroyed following obtaining the blastomere. 50-61. (canceled)
 62. Ahuman TS cell derived from a human embryo but without destroying thehuman embryo, produced by the method of claim
 49. 63. (canceled)
 64. Adifferentiated cell or tissue derived from the TS cell of claim
 62. 65.A method of producing a human TS cell line without human embryodestruction comprising the step of culturing the human TS cell of claim62 to produce a TS cell line.
 66. A human TS cell line produced by themethod of claim
 65. 67. A method of isolating a blastomere from anembryo comprising: (a) immobilizing the embryo; and (b) tapping theimmobilized embryo until a blastomere is isolated. 68-71. (canceled) 72.A method of using the ES cell of claim 31 for the manufacture of amedicament for treating a disorder amenable to cell therapy in apatient.
 73. A method of using the differentiated cell or tissue ofclaim 36 for the manufacture of a medicament for treating a disorderamenable to cell therapy in a patient.
 74. A method of using the TS cellof claim 62 for the manufacture of a medicament for treating a disorderamenable to cell therapy in a patient.
 75. A method of conductingembryonic stem cell research without destroying a human embryo,comprising obtaining a human ES cell or ES cell line derived from ahuman embryo but without destroying the human embryo; and conductingembryonic stem cell research using the human ES cell or ES cell line.76. (canceled)
 77. A method of producing an embryonic stem (ES) cell orembryo-derived (ED) cell, comprising the step of culturing a blastomereobtained from an embryo, wherein the embryo remains viable.
 78. A methodof producing an embryonic stem (ES) cell, comprising: (a) culturing ablastomere obtained from a mammalian embryo to generate a cluster of twoor more blastomeres; (b) directly or indirectly contacting the culturedcluster of two or more blastomeres with embryonic or fetal cells; and(c) culturing the cluster of two or more blastomeres of (b) until EScells are produced. 79-99. (canceled)
 100. A method of producing EScells, comprising (a) obtaining a blastomere from a mammalian embryo;(b) culturing the blastomere to generate a cluster of two or moreblastomeres; (c) aggregating the cluster of two or more blastomeres withembryonic or fetal cells; (d) culturing the aggregated cluster of two ormore blastomeres and the embryonic or fetal cells until the aggregatedcluster of blastomeres exhibits properties of ES cells; and (e)isolating the ES cells derived from the blastomere from the embryoniccells. 101-113. (canceled)
 114. An ES cell derived from a mammalianembryo but without destroying the mammalian embryo produced by themethod of claim
 78. 115. A method of producing TS cells, comprising (a)obtaining a blastomere from a mammalian embryo; (b) culturing theblastomere to generate a cluster of two or more blastomeres; (c)aggregating the cluster of two or more blastomeres with embryonic orfetal cells; (d) obtaining outgrowths from the cluster of two or moreblastomeres, wherein the outgrowths exhibit properties of trophoblast orextraembryonic endoderm cells; (e) contacting the outgrowths with FGF-4to produce TS cells; and (f) isolating the TS cells derived from theblastomere.
 116. The method of claim 115, wherein the mammalian embryois a human embryo and the TS cells are human cells.
 117. A method ofproducing a TS cell line comprising the step of culturing the TS cellsof claim 116 to produce a TS cell line.
 118. A method of producing humanembryonic stem (ES) cells, comprising: (a) culturing a blastomereobtained from a human embryo in medium containing less than 5 mM glucoseto generate a cluster of two or more blastomeres; (b) directly orindirectly contacting the cultured cluster of two or more blastomereswith medium sufficient to promote the growth and survival of thecultured cluster of two or more blastomeres; and (c) culturing thecluster of two or more blastomeres of (b) to produce ES cells. 119-121.(canceled)